

**UNITED STATES AIR FORCE
RESEARCH LABORATORY**

**IN VITRO RAT HEPATOCYTE TOXICITY
AND BACTERIA GENOTOXICITY
EVALUATION OF HIGH ENERGY
CHEMICALS FOR REPLACEMENT OF
HYDRAZINE**

S. Husain

MANTECH ENVIRONMENTAL TECHNOLOGY, INC.
PO BOX 31009
DAYTON, OH 45437-0009

S. Sharma

P. Gao

MANTECH ENVIRONMENTAL TECHNOLOGY, INC.
RESEARCH TRIANGLE PARK, NC

D. Mattie

J. Frazier

OPERATIONAL TOXICOLOGY BRANCH
HUMAN EFFECTIVENESS DIRECTORATE
AIR FORCE RESEARCH LABORATORY
WRIGHT-PATTERSON AFB, OH 45433-7400

December 2002

Final Report - December 1999 - December 2001

**Human Effectiveness Directorate
Deployment and Sustainment Division
Operational Toxicology Branch
2856 G Street
Wright-Patterson AFB OH 45433-7400**

Approved for public release; distribution is unlimited.

20040706 107

NOTICES

When US Government drawings, specifications or other data are used for any purpose other than a definitely related Government procurement operation, the Government thereby incurs no responsibility nor any obligation whatsoever, and the fact that the Government may have formulated, furnished, or in any way supplied the said drawings, specifications, or other data is not to be regarded by implication or otherwise, as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use, or sell any patented invention that may in any way be related thereto.

Please do not request copies of this report from the Air Force Research Laboratory. Additional copies may be purchased from:

National Technical Information Service
5285 Port Royal Road
Springfield, Virginia 22161

Federal Government agencies and their contractors registered with the Defense Technical Information Center should direct requests for copies of this report to:

Defense Technical Information Service
8725 John J. Kingman Rd., Ste 0944
Ft. Belvoir, Virginia 22060-6218

DISCLAIMER

This Technical Report is published as received and has not been edited by the Technical Editing Staff of the Air Force Research Laboratory.

TECHNICAL REVIEW AND APPROVAL

AFRL-HE-WP-TR-2003-0077

The animal use described in this study was conducted in accordance with the principles stated in the "Guide for the Care and Use of Laboratory Animals", National Research Council, 1996, and the Animal Welfare Act of 1966, as amended.

This report has been reviewed by the Office of Public Affairs (PA) and is releasable to the National Technical Information Service (NTIS). At NTIS, it will be available to the general public, including foreign nations.

This technical report has been reviewed and is approved for publication.

FOR THE DIRECTOR



MARK M. HOFFMAN
Deputy Chief, Deployment and Sustainment Division
Air Force Research Laboratory

REPORT DOCUMENTATION PAGE

*Form Approved
OMB No. 0704-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

| | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|--|
| 1. AGENCY USE ONLY (Leave blank) | | 2. REPORT DATE December 2002 | 3. REPORT TYPE AND DATES COVERED Final Report - December 1999 - December 2001 | |
| 4. TITLE AND SUBTITLE In Vitro Rat Hepatocyte Toxicity and Bacteria Genotoxicity Evaluation of High Energy Chemicals for Replacement of Hydrazine | | | 5. FUNDING NUMBERS Contract F33615-00-C-6060 PE 61102F PR 2312 TA 2312A2 WU 2312A205 | |
| 6. AUTHOR(S) Hussain, S., Sharma, S., Gao, P., Mattie, D., Frazier, J. | | | | |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Human Effectiveness Directorate ** Air Force Research Laboratory Wright-Patterson AFB, OH 45433-7400 | | | 8. PERFORMING ORGANIZATION REPORT NUMBER | |
| 9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) ManTech Environmental Technology, Inc. * PO Box 31009 Dayton, OH 45437-0009 | | | 10. SPONSORING/MONITORING AGENCY REPORT NUMBER AFRL-HE-WP-TR-2003-0077 | |
| 11. SUPPLEMENTARY NOTES | | | | |
| 12a. DISTRIBUTION AVAILABILITY STATEMENT Approved for public release; distribution is unlimited. | | | 12b. DISTRIBUTION CODE | |
| 13. ABSTRACT (Maximum 200 words) In an effort to develop methods to predict the toxicological response of newly synthesized chemicals that are of interest to the US Air Force, in vitro rat hepatocyte toxicity and bacteria (Salmonella) genotoxicity assays were performed on thirteen high-energy chemicals (HEC) that were selected as potential replacements of hydrazine. The HECs were primarily hydrazine derivatives (hydrazinium nitrate, HZN; 2-hydroxyethylhydrazine nitrate, HEHN; diethyl hydrazine nitrate, DEHN; 1,4-dihydrazine nitrate, DHTN; methylhydrazine nitrate, MHN; diaminoguanidine nitrate, DAGN; 2,2-dimethyltriazanium nitrate, DMTN; nitroaminoguanidine nitrate, NAGN), amino containing compounds (ethanolamine nitrate, EAN; histamine dinitrate, HDN; methoxylamine nitrate, MAN), and triazole containing compounds (1,2,4-triazole nitrate, TN; 4-amino-1,2,4-triazole nitrate, ATN). The results in hepatocytes showed a dose dependent decrease in mitochondrial activity (MTT), increase in lactate dehydrogenase (LDH) leakage, and depletion of GSH levels. Responses to hydrazine were used as reference values for ranking the other HECs. According to the MTT assay, the hydrazine-containing compounds are the most toxic (HZN > DEHN > DHTN > MHN > HEHN > DAGN > NAGN), amino-containing compounds displayed medium toxicity (HDN > EAN > MAN) and triazole-containing compounds exhibited low toxicity (DMTN > ATN > TN). Results of genotoxicity (Ames assay) on 10 of the 13 HECs indicated that HZN, DHTN and MAN were mutagenic. DHTN was a direct mutagen causing AT and GC base-pair substitutions and frameshift mutations. | | | | |
| 14. SUBJECT TERMS hydrazinium nitrate, HZN 2-hydroxyethylhydrazine nitrate, HEHN diethyl hydrazine nitrate, DEHN | | | 15. NUMBER OF PAGES 83 | |
| | | | 16. PRICE CODE | |
| 17. SECURITY CLASSIFICATION OF REPORT UNCLASSIFIED | 18. SECURITY CLASSIFICATION OF THIS PAGE UNCLASSIFIED | 19. SECURITY CLASSIFICATION OF ABSTRACT UNCLASSIFIED | 20. LIMITATION OF ABSTRACT UL | |

THIS PAGE INTENTIONALLY LEFT BLANK.

TABLE OF CONTENTS

SECTION I. TOXICOLOGICAL ASSESSMENT OF HIGH ENERGY COMPOUNDS: *IN VITRO* HEPATOCYTE TOXICITY

| | |
|--------------------|----|
| SUMMARY | 1 |
| INTRODUCTION | 2 |
| METHODS | 3 |
| RESULTS | 6 |
| DISCUSSION | 15 |
| REFERENCES | 16 |

SECTION II. GENOTOXICITY ASSAYS FOR ELEVEN HIGH ENERGY COMPOUNDS: *SALMONELLA* / MICROSOME MUTAGENESIS ASSAY

| | |
|--------------------|----|
| SUMMARY | 18 |
| INTRODUCTION | 20 |
| METHODS | 20 |
| RESULTS | 23 |
| DISCUSSION | 55 |
| REFERENCES | 56 |

| | |
|----------------------------------------------------------------------------------|----|
| APPENDIX II-A: Raw Data of <i>Salmonella</i> / Microsome Mutagenesis Assay | 57 |
|----------------------------------------------------------------------------------|----|

LIST OF FIGURES

| | |
|--------------------------------------------------------------------------------------------------------|----|
| Figure I-1: Schedule for Culturing and Dosing of Primary Hepatocytes | 5 |
| Figure I-2. Effect of HEC on Mitochondrial Function of Hepatocytes | 7 |
| Figure I-3. Effect of HEC on LDH Leakage of Rat Hepatocytes..... | 9 |
| Figure I-4. Effect of HEC on GSH Levels in Hepatocytes..... | 11 |
| Figure I-5. Effect of HEC on ROS Generation in Hepatocytes | 13 |
| | |
| Figure II-1: Mutant Revertants Induced by HZN in TA1535 with and without S9 Activation System..... | 40 |
| Figure II-2: Mutant Revertants Induced by HZN in TA102 with S9 Activation System..... | 41 |
| Figure II-3: Mutant Revertants Induced by DHTN in TA102 with and without S9 Activation System..... | 43 |
| Figure II-4: Mutant Revertants Induced by DHTN in TA1535 with and without S9 Activation System..... | 44 |
| Figure II-5: Mutant Revertants Induced by MAN in TA100 with and without S9 Activation System..... | 47 |

LIST OF TABLES

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------|----|
| TABLE I-1: PROPOSED HIGH-ENERGY CHEMICALS (HEC) | 3 |
| TABLE I-2: CALCULATED EC ₇₅ , LOWEST EFFECTIVE CONCENTRATION (LEC), EC ₂₅ AND EC ₅₀ VALUES OF HEC | 15 |
| | |
| TABLE II-1: GENOTYPE CONFIRMATION OF TESTER STRAINS | 24 |
| TABLE II-2: CONVERSION OF mg/PLATE TO mM CONCENTRATION FOR EACH CHEMICAL IN THE DOSE SELECTION ASSAY | 24 |
| TABLE II-3: RESULTS OF DOSE SELECTION ASSAYS FOR HZN..... | 25 |
| TABLE II-4. RESULTS OF DOSE SELECTION ASSAYS FOR DEHN..... | 26 |
| TABLE II-5: RESULTS OF DOSE SELECTION ASSAYS FOR DHTN..... | 27 |
| TABLE II-6: RESULTS OF DOSE SELECTION ASSAYS FOR DAGN | 28 |
| TABLE II-7. RESULTS OF DOSE SELECTION ASSAYS FOR NAGN | 29 |
| TABLE II-8. RESULTS OF DOSE SELECTION ASSAYS FOR EAN..... | 30 |
| TABLE II-9: RESULTS OF DOSE SELECTION ASSAYS FOR HDN | 31 |
| TABLE II-10: RESULTS OF DOSE SELECTION ASSAYS FOR MAN | 32 |
| TABLE II-11: RESULTS OF DOSE SELECTION ASSAYS FOR TN | 33 |
| TABLE II-12. RESULTS OF DOSE SELECTION ASSAYS FOR ATN..... | 34 |
| TABLE II-13. RESULTS OF DOSE SELECTION ASSAYS FOR DMTN | 35 |
| TABLE II-14: MUTAGENICITY ASSAY RESULTS OF HZN..... | 39 |
| TABLE II-15: MUTAGENICITY ASSAY RESULTS OF DHTN | 42 |
| TABLE II-16: MUTAGENICITY ASSAY RESULTS OF HDN..... | 45 |
| TABLE II-17: MUTAGENICITY ASSAY RESULTS OF MAN | 46 |
| TABLE II-18: MUTAGENICITY ASSAY RESULTS OF DMTN..... | 48 |
| TABLE II-19: MUTAGENICITY ASSAY RESULTS OF DAGN..... | 49 |
| TABLE II-20: MUTAGENICITY ASSAY RESULTS OF NAGN..... | 50 |
| TABLE II-21: MUTAGENICITY ASSAY RESULTS OF EAN | 51 |
| TABLE II-22: MUTAGENICITY ASSAY RESULTS OF TN | 52 |
| TABLE II-23: MUTAGENICITY ASSAY RESULTS OF ATN | 53 |
| TABLE II-24: EXPERIMENTAL SUMMARY OF 11 HIGH ENERGY CHEMICALS..... | 54 |
| | |
| TABLE II-A1: MUTAGENICITY ASSAY RESULTS OF HZN | 58 |
| TABLE II-A2: MUTAGENICITY ASSAY RESULTS OF DHTN | 60 |
| TABLE II-A3: MUTAGENICITY ASSAY RESULTS OF HDN..... | 62 |
| TABLE II-A4: MUTAGENICITY ASSAY RESULTS OF MAN | 64 |
| TABLE II-A5: MUTAGENICITY ASSAY RESULTS OF DMTN..... | 66 |
| TABLE II-A6: MUTAGENICITY ASSAY RESULTS OF DAGN..... | 68 |
| TABLE II-A7: MUTAGENICITY ASSAY RESULTS OF NAGN..... | 70 |
| TABLE II-A8: MUTAGENICITY ASSAY RESULTS OF EAN | 72 |
| TABLE II-A9: MUTAGENICITY ASSAY RESULTS OF TN | 74 |
| TABLE II-A10: MUTAGENICITY ASSAY RESULTS OF ATN | 76 |

PREFACE

This document is part of the final reporting process for the Air Force Research Laboratory/Operational Toxicology Branch (AFRL/HEST) project "Toxicity of High Energy Chemicals" (JON# 2312A205). This preliminary toxicology report is divided into two sections. Section I provides information on *in vitro* hepatocyte toxicity evaluations. These investigations were performed at AFRL/HEST, Wright Patterson Air Force Base, Ohio. Section II provides information on genotoxicity evaluations. These studies were performed by the Cellular and Molecular Toxicology Program, ManTech Environmental Technology, Inc., Research Triangle Park, North Carolina. The Toxicity of High Energy Chemicals research project was funded by the Air Force Office of Scientific Research (AFOSR) and was initiated in April 1999, under Department of the Air Force Contract No. F41624-96-C-9010 and completed under Contract No. F33615-00-C-6060. Dr. Richard R. Stotts served as the Contracting Officer's Representative for the U.S. Air Force. Darol E. Dodd, Ph.D., served as Program Manager for ManTech Geo-Centers Joint Venture. Authors would like to acknowledge TSgt Gerri Miller, TSgt Michelle Curran and Darin Minnick for their excellent technical support.

**IN VITRO RAT HEPATOCYTE TOXICITY AND BACTERIA GENOTOXICITY
EVALUATION OF HIGH ENERGY CHEMICALS FOR REPLACEMENT OF
HYDRAZINE**

SECTION I. TOXICOLOGICAL ASSESSMENT OF HIGH ENERGY COMPOUNDS: *IN VITRO* HEPATOCYTE TOXICITY

Prepared by Saber Hussain, PhD (Operational Toxicology Research, ManTech Environmental Technology, Inc., Dayton, OH), David R. Mattie, PhD, and John M. Frazier, PhD (AFRL/HEST, Wright-Patterson AFB, OH).

SUMMARY

In an effort to develop methods to predict the toxicological response of newly synthesized chemicals that are of interest to the U.S. Air Force, we have evaluated the *in vitro* toxicity for thirteen high-energy chemicals (HEC) in rat hepatocytes. Hydrazine is an aircraft fuel and propellant used by the US Air Force. Due to its toxicity the Propulsion Directorate of the Air Force Research Laboratory (AFRL/PR) has synthesized a series of high-energy chemicals (HECs) as potential hydrazine replacements. The HECs are comprised primarily of hydrazine derivatives (hydrazinium nitrate, HZN; 2-hydroxyethylhydrazine nitrate, HEHN; diethyl hydrazine nitrate, DEHN; 1,4-dihydrazine nitrate, DHTN; methylhydrazine nitrate, MHN; diaminoguanidine nitrate, DAGN; 2, 2-dimethyltriazanium nitrate, DMTN; nitroaminoguanidine nitrate, NAGN), amino containing compounds (ethanolamine nitrate, EAN; histamine dinitrate, HDN; methoxylamine nitrate, MAN), and triazole containing compounds (1,2,4-triazole nitrate, TN; 4-amino-1,2,4-triazole nitrate, ATN). The current study was undertaken to examine the toxicity of HECs in rat (male Fischer 344) primary hepatocytes *in vitro*. The effects of short-term exposure (4 hours) of hepatocytes to HECs were investigated with reference to viability, mitochondrial function, reactive oxygen species generation, reduced and oxidized glutathione (GSH and GSSG). The results showed a dose dependent decrease in mitochondrial activity (MTT), increase in lactate dehydrogenase (LDH) leakage, and depletion of GSH levels. Responses to hydrazine were used as reference values for ranking the other HECs. According to the MTT assay, the hydrazine-containing compounds are the most toxic (HZN > DEHN > DHTN > MHN > HEHN > DAGN > NAGN), amino-containing compounds displayed medium toxicity (HDN > EAN > MAN) and triazole-containing compounds exhibited low toxicity (DMTN > ATN > TN). In conclusion, based on these biochemical data, the chemicals were classified into three categories: higher toxicity (hydrazine containing compounds), medium toxicity (amino containing compounds), and lower toxicity (triazole containing compounds).

INTRODUCTION





Hydrazine is a highly reactive chemical that has been used as a propellant by the US Air Force. Besides its application as a propellant and fuel in aircraft, hydrazine has a wide range of uses, including corrosion inhibitors, photographic materials and drugs. Several hydrazine derivatives occur naturally in tobacco and mushrooms, some are herbicides, and others have been shown to be pharmacologically active. Hydrazine and its derivatives enter the environment primarily from aerospace emissions and from manufacturing facilities although exposure also occurs as a metabolite of the drugs isoniazid (an antitubercular agent) and hydralazine (an antihypertensive agent) (Delaney and Timbrell, 1995). Toxic effects due to exposure to hydrazines include liver damage (Kleineke *et al.*, 1979), hypoglycemia, disorders of the central nervous system (Lightcap *et al.*, 1995), interference with intermediary metabolism (Moloney and Prough, 1983) and carcinogenicity (Bosan *et al.*, 1987; Wald *et al.*, 1984).

Several investigators have reported on the toxicity of hydrazine *in vivo* and *in vitro*. Hydrazine exposure leads to ATP depletion and megamitochondria formation *in vivo* (Kerai and Timbrell 1997; Preece *et al.*, 1990; Wakabayashi *et al.*, 2000). Hydrazine inhibits the mitochondrial enzyme succinate dehydrogenase (Ghatineh *et al.*, 1992), which subsequently reduces mitochondrial function. Hydrazine also produces toxicity by interfering with a number of metabolic processes such as gluconeogenesis (Kleineke *et al.*, 1979) and glutamine synthetase (Willis 1966; Sendo *et al.*, 1984; Kaneo *et al.*, 1984).

The disappearance of hydrazine from hepatic microsomes suggested that hydrazine was oxidized by the cytochromes P450, although the product was not identified (Jenner and Timbrell, 1994). A study aimed to ascertain the role of P450 isozymes in the toxicity of hydrazine using rat hepatocytes *in vitro* suggested that metabolism by all three P450 isozymes leads to detoxification and that the cytotoxicity of hydrazine could be due to the parent compound (Delaney and Trimbel, 1995).

The US Air Force continues to evaluate alternative aerospace propellants. In view of hydrazine's toxicity, a series of thirteen high-energy chemicals (HEC) was synthesized by the Propulsion Directorate of the Air Force Research Laboratory, CA (Table I-1). In order to maintain a safe working environment, it is necessary to develop reliable, rapid and inexpensive methods for predicting health risks of newly developed chemicals. The aim of this study was to examine the toxicity of these HEC in primary hepatocytes *in vitro* with reference to viability, mitochondrial function, and redox status of the cells. The toxicological profiles of these chemicals will assist in the design and optimization of chemicals for new propellants.

TABLE I-1: PROPOSED HIGH-ENERGY CHEMICALS (HEC)

| Chemical Name | Abbreviation | Neutral Species | Category |
|-----------------------------------|--------------|--------------------------------------------------------------------------------------|--------------------------|
| Hydrazinium nitrate | HZN | NH_2NH_2 | hydrazine |
| 2-Hydroxyethylhydrazinium nitrate | HEHN | $\text{NH}_2\text{NHCH}_2\text{CH}_2\text{OH}$ | hydrazine |
| 1,2-Diethylhydrazinium nitrate | DEHN | $\text{CH}_3\text{CH}_2\text{NHNHCH}_2\text{CH}_3$ | hydrazine |
| Methylhydrazinium nitrate | MHN | CH_3NHNH_2 | hydrazine |
| Diaminoguanidine nitrate | DAGN | $\text{NHC}(\text{NHNH}_2)_2$ | hydrazine |
| Ethanolamine nitrate | EAN | $\text{NH}_2\text{CH}_2\text{CH}_2\text{OH}$ | amine |
| Histamine dinitrate | HDN |  | amine |
| Methoxylamine nitrate | MAN | NH_2OCH_3 | amine |
| 1,2,4-Triazole nitrate | TN |  | triazole |
| 4-Amino-1,2,4-Triazole nitrate | ATN |  | triazole |
| 2,2-Dimethyltriazanium nitrate | DMTN | $[(\text{NH}_2)_2\text{N}(\text{CH}_3)_2]^+$ | quaternary ammonium salt |
| 1,4-Dihydrazinotetrazine nitrate | DHTN |  | hydrazine |
| Nitroaminoguanidine nitrate | NAGN | $\text{NH}_2\text{NHC}(\text{NH})\text{NHNO}_2$ | hydrazine |

METHODS

Chemicals

Collagenase was obtained from Boehringer-Mannheim Biochemicals (Indianapolis, IN). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), β -nicotinamide-adenine dinucleotide-reduced (NADH), 2'-7'-dichlorodihydrofluorescein diacetate (DCFH-DA), reduced glutathione (GSH), insulin/transferrin/sodium selenite (ITS) additive, gentamicin, and dexamethasone were purchased from Sigma Chemical Company (St. Louis, MO). Chee media was obtained from Gibco (Grand Island, NY). All HEC were supplied from the Propulsion Directorate of the Air Force Research Laboratory, Edwards Air Force Base, CA. These compounds may be categorized as hydrazine-based, amine-based, triazole-based, and a quaternary ammonium salt as shown in Table I-1.

Animals

Male Fischer 344 rats (225-300 g) were obtained from Charles River Laboratories (Wilmington, MA). Rats were anesthetized with 1 mL/kg of a mixture of ketamine (70 mg/L; Parke-Davis, Moris Plains, NJ) and xylazine (6 mg/L; Mobay Corp., Shawnee, KS) prior to undergoing liver perfusion. All animals used in this study were handled in accordance with the principles stated in *Guide for the Care and Use of Laboratory Animals*, Institute of Laboratory Animal Resources, National Research Council, National Academy Press, 1996, and the Animal Welfare Act of 1966, as amended.

Liver Perfusion, Hepatocytes Enrichment and Culture

Fischer 344 rat livers were perfused, and hepatocytes were isolated and enriched by the two-step Seglen procedure (Seglen, 1976) with minor modifications as previously described (DelRaso and Frazier 1999). Chee media for perfusion (pH 7.2) were supplemented with 15 mM HEPES, washout medium was supplemented with heparin (2.0 U/mL) and EGTA (0.5 mM), and digestion medium was supplemented with 500 mg/L collagenase. Viable primary rat hepatocytes were enriched by low speed centrifugation (500 x g) for 3 min. Typically the yield of isolated hepatocytes was from 300 to 400 million cells with viability ranging from 85 to 95% as determined by trypan blue dye exclusion. For cell culture studies, suspensions of primary hepatocytes were adjusted to a cell density of 1.0×10^6 cell/mL in Chee culture medium (pH 7.2) supplemented with HEPES (10 mM), insulin/transferrin/sodium selenite solution (5 mg/L, 5 mg/L, 5 μ g/L), gentamicin (50 mg/L), and dexamethasone (0.4 mg/mL). Cells were seeded in either 96-well (4×10^4 cells/well) or 6-well (1.0×10^6 cells/well) culture plates previously coated with rat tail collagen, 1.0 μ g/well or 25 μ g/well, respectively. After 4 h of incubation in a 5% CO₂ incubator at 37°C to allow for attachment, hepatocytes were re-fed with Chee culture medium lacking dexamethasone. Hepatocytes were cultured for an additional 21 h before treatment as indicated in the experimental schedule (see Figure I-1).




Figure I-1: Schedule for Culturing and Dosing of Primary Hepatocytes.

Fischer 344 rat livers were perfused, and hepatocytes were isolated and enriched as described in Material and Methods. After 4 h of incubation to allow for attachment, hepatocytes were re-fed with Chee culture medium and incubated for a further 20 h prior to HEC exposure. Hepatocytes were exposed to hydrazine for 4 h and biochemical evaluations were conducted immediately at the end of the exposure.

Treatment

Primary rat hepatocytes were treated with various concentrations of HEC dissolved in Chee culture media. The cells were exposed to HEC for 4 h (Figure I-1). A number of toxicity end points were evaluated at the end of the 4 h incubation period.

Mitochondrial Function

Mitochondrial function was determined spectrophotometrically by measuring the degree of mitochondrial reduction of the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan by succinic dehydrogenase (Carmichael *et al.*, 1987). Following treatment, cells were washed and incubated at 37°C in Chee media containing 0.05% MTT for 30 min. At this time the media containing MTT was removed and the colored product (formazan) extracted from the cells in acidified isopropanol and assayed with a spectraMAX plus microplate reader (Molecular Devices, Sunnyvale, CA.).

LDH Leakage

LDH leakage indicates loss of cellular viability because membrane damage that results in LDH leakage is generally considered irreversible. LDH leakage was assessed by measuring the activity of LDH in the cells and released into the media (Moldeus *et al.*, 1978). After treatment, the media was removed from the culture plate and placed on ice. The plates were washed with

cold PBS followed by addition of 1 ml of a 0.5% solution of Triton X-100. The cells were placed on ice for 30 min at which time the solution and cellular debris were carefully removed and vortexed in 2 ml sample vials. Aliquots (10 μ l) of the media or detergent solution were then assayed in phosphate buffer containing 0.2 mM NADH and 1.36 mM pyruvate by monitoring the loss rate of NADH absorption at 340 nm with a spectraMAX Plus microplate reader (Molecular Devices, Sunnyvale, CA). The percent of activity in the media was then calculated by dividing the amount of activity in the media by the total activity.

Reduced Glutathione

Glutathione (GSH) is a ubiquitous sulfhydryl-containing molecule in cells that is responsible for maintaining cellular oxidation-reduction homeostasis. Monitored changes in GSH homeostasis are an indication of cell damage. Reduced glutathione (GSH) were measured according to the Glutathione Assay Kit from Cayman Chemical Company, Ann Arbor, MI. The assay is based on enzymatic recycling method, using glutathione reductase and DTNB (5,5'-dithiobis-2-nitrobenzoic acid, Ellman's reagent) as described by Tietze (1969).

ROS Generation

ROS generation was determined by the method described by Wang and Joseph (1999). Cells were incubated with 100 μ M of 2'-7'-dichlorodihydrofluorescein diacetate (DCFH-DA), in Chee media under standard culture conditions for 30 min prior to chemical treatment. The DCFH-DA is cell permeable and can be oxidized into fluorescent product 2,7-dichlorofluorecein. After the media containing DCFH-DA was removed, the cells were washed and treated with test chemicals in Chee media for 4 hours. At the end of the exposure, the cells were washed with PBS and fluorescence of the cells from each well was measured in a spectraMAX (Molecular Devices, Sunnyvale, CA.) multi-well fluorescence plate reader at excitation 485 nm and emission at 530 nm.


RESULTS

***In vitro* toxicity of HEC**


The MTT assay was used to assess the effects of HEC on mitochondrial function of rat hepatocytes. Figure I-2 shows that mitochondrial function of hepatocytes decreases in a dose-dependent manner with increasing HEC concentration. Hydrazine-containing compounds (HZN, HEHN, DEHN, MHN, DHTN, DAGN, and NAGN) reduced mitochondrial function in a concentration-dependent manner. Amino-containing compounds (EAN, HDN, and MAN) displayed toxicity at higher doses except for HDN, which showed toxicity at 50 mM. Triazole containing compounds (TN, ATN, and DMTN) did not exhibit significant toxicity even at the highest dose (150 mM). According to the MTT assay, the hydrazine-containing compounds are

the most toxic, the amino-containing compounds displayed medium toxicity, and the triazole-containing compounds exhibited low toxicity.

I-2A



I-2B



I-2C





Figure I-2. Effect of HEC on Mitochondrial Function of Hepatocytes.


MTT reduction is plotted as a function of HEC dose for hydrazine-based HEC in (A), for amine-based HEC in (B) and for triazole-based HEC (C). Primary hepatocytes were treated with different concentrations of HEC for 4 h. At the end of the incubation period, mitochondrial function was determined by the MTT assay as described in the Materials and Methods section. The data are expressed as means \pm SD of three independent experiments from three different rats. (*) indicates a statistically significant difference compared to controls ($p < 0.05$).

The viability of rat hepatocytes was evaluated by measuring the leakage of LDH into the media. Figure I-3 indicates that 4-h exposure to HEC produced a dose-dependent increase in LDH leakage into the media. HZN appears to be more toxic as it induced 80-90% LDH leakage at 150 mM HZN. The EC_{50} value for HZN is 62 mM. The trend of toxicity as assessed by LDH leakage follows the same trend seen in the MTT assay except that EAN produced higher toxicity compared to HDN and MAN. LDH leakage showed that the order of toxicity as follows: hydrazine-containing compounds > amino-containing compounds > triazole-containing compounds.

I-3A



I-3B







Figure I-3. Effect of HEC on LDH Leakage of Rat Hepatocytes.


LDH leakage into media is plotted as a function of HEC dose for hydrazine-based HEC in (A), for amine-based HEC in (B) and for triazole-based HEC (C). Primary hepatocytes were treated with different concentrations of HEC for 4 h. At the end of the incubation period, LDH leakage was determined by the LDH assay as described in the Materials and Methods section. The data are expressed as means \pm SD of three independent experiments from three different rats. (*) indicates a statistically significant difference compared to controls ($p < 0.05$).

In cells, glutathione (GSH) is a ubiquitous sulfhydryl-containing molecule that is responsible for maintaining cellular oxidation-reduction homeostasis. GSH protects cells against damage by scavenging highly reactive free radicals that can interact with critical cellular components. Monitored changes in GSH homeostasis are therefore an indication of cell damage. A dose-dependent decrease in GSH was found in HEC-treated hepatocytes as seen in Figure I-4. GSH levels were measured in control and HEC-exposed cells after 4 hours of exposure. DHTN was found to reduce considerably GSH levels to 4% at 25 mM. A large depletion (70%) of GSH resulted from low dose (25 mM) of HZN followed by subsequent decreases at 50, 100 and 150 mM. The order of toxicity of hydrazine-containing compounds in reducing GSH levels are DHTN > HZN > DEHN > MHN > HEHN > DAGN > NAGN. Based on GSH assay, the most toxic chemical is DHTN.

I-4A



I-4B



I-4C





Figure I-4. Effect of HEC on GSH Levels in Hepatocytes.


GSH content is plotted as a function of HEC dose for hydrazine-based HEC in (A), for amine-based HEC in (B) and for triazole-based HEC (C). Primary hepatocytes were treated with different concentrations of HEC for 4 h. At the end of the exposure, cells were washed with PBS, and GSH levels were measured as described in the Materials and Methods section. The data are expressed as means \pm SD of three independent experiments with hepatocytes from three different rats. (*) indicates a statistically significant difference compared to controls ($p < 0.05$).

Dichlorofluorescein diacetate (DCFH-DA) is widely used to measure reactive oxygen species (ROS) generation in cells. The ROS generation following exposure to HEC is shown in Figure I-5. Even a low dose of HZN (25 mM) produced a significant increase in ROS generation at the end of the 4-h exposure. The HZN treatment at 100 and 150 mM resulted in an approximately eight-fold increase in ROS. HZN is the most toxic followed by DAGN and MHN. Other hydrazine-containing compounds (HEHN, DEHN, NAGN, and DHTN) did not show significant increase in ROS. Among amino-containing compounds, HDN caused the greatest increase in ROS. An increase in ROS was observed in EAN-treated cells at higher dose (150 mM), although there was no significant effect observed in MAN-exposed cells. No appreciable increase in ROS generation was observed for cells treated with triazole-containing compounds (TN, ATN, and DMTN). Using ROS generation as a measure of toxicity, HZN was the most toxic of the HEC.

I-5A



I-5B



I-5C




Figure I-5. Effect of HEC on ROS Generation in Hepatocytes.

The increase in ROS generation (fold of increase in fluorescence intensity) is plotted as a function of HEC dose for hydrazine-based HEC in (A), for amine-based HEC in (B) and for triazole-based HEC (C). Primary hepatocytes were incubated with DCFH-DA for 30 min. After DCFH-DA containing medium was removed, the cells were washed and treated with HEC in Chee media for 4 h. At the end of exposure, fluorescence was measured as described in Materials and Methods section and the intensity of fluorescence expressed in fold increase in treated cells with respect to control. The data are expressed as means \pm SD of three independent experiments with hepatocytes from three different rats. (*) indicates a statistically significant difference compared to controls ($p < 0.05$).

Toxicity Comparison

In order to compare the results of the assays using values representative of a dose-response curve, the following parameters were determined: The lowest effective concentration (LEC) was determined for ROS and effective concentrations (EC) were determined for MTT, LDH, and GSH. The EC_{75} was determined in order to maximize the number of data points for MTT. Similarly, the EC_{25} was determined for LDH and the median effective concentration (EC_{50}) was determined for GSH. Many of these endpoints, displayed in Table I-2, can only be expressed as lower limits from the dose-response curves (greater than 150 mM).

TABLE I-2: CALCULATED EC₇₅, LOWEST EFFECTIVE CONCENTRATION (LEC), EC₂₅ AND EC₅₀ VALUES OF HEC

| Propellants | MTT EC ₇₅ (mM) | ROS LEC (mM) | LDH EC ₂₅ (mM) | GSH EC ₅₀ (mM) |
|-------------|------------------------------|-----------------|------------------------------|------------------------------|
| HZN | 35 | 5 | 20 | 20 |
| HEHN | 68 | >150 | 75 | 116 |
| DEHN | 50 | >150 | 65 | 32 |
| MHN | 18 | 7 | >150 | 58 |
| DAGN | 110 | 30 | >150 | 145 |
| EAN | 115 | 105 | 30 | 144 |
| HDN | 58 | 25 | >150 | 80 |
| MAN | 150 | >150 | >150 | >150 |
| TN | >150 | >150 | >150 | >150 |
| ATN | >150 | >150 | >150 | >150 |
| DMTN | >150 | >150 | >150 | >150 |
| DHTN | 32 | >150 | 30 | 4 |
| NAGN | >150 | >150 | >150 | >150 |

DISCUSSION

ROS are by-products of biological redox reactions and are involved in various pathological conditions (Farber *et al.*, 1990). A large increase in ROS results from a low dose of HZN among all HEC compounds. Increased generation of ROS by HEC is likely to contribute to oxidative stress that may ultimately manifest cytotoxicity. Increase in intracellular ROS, often referred to as oxidative stress, represents a potentially toxic insult, which, if not counteracted, will lead to membranous dysfunction, as well as protein and DNA damage (Preece and Timbrell 1989; Loft and, Poulsen 1999). The toxicity of HEC, revealed by LDH release and MTT reduction, is strongly correlated to ROS generation and indicates induction of massive oxidative stress *in vitro* in primary cultures of rat hepatocytes.

Glutathione is the principal intracellular non-protein thiol that is the major source of reducing power in the cell (Sies, 1999). It provides a primary defense against oxidative stress by its ability to scavenge free radicals. The results reported here show a dose-dependent depletion of GSH by HEC. It is interesting to note that low dose (25 mM) of HZN greatly depleted GSH compared to other HEC, which did not occur to any notable extent for either MTT reduction or LDH leakage. GSH depletion in primary culture of rat hepatocytes exposed to HEC is strongly correlated to the increased ROS generation. It is possible that GSH depletion makes cells produce reactive oxygen species. Previously, it has been shown the loss of GSH, an important cellular antioxidant, increased endogeneous ROS to toxic levels in hepatocytes (Anundi *et al.*, 1979). It has been postulated that the loss of GSH and catalase may compromise cellular antioxidant defenses and lead to the accumulation of ROS that are generated as by-products of normal cellular function (Hussain and Frazier 2001; Hussain *et al.*, 1999).

The major events in HEC cytotoxicity of primary rat hepatocytes are the reduction of mitochondrial function, generation of ROS and GSH depletion. It is not known the exact mechanism of action of these chemicals, but the depletion of GSH and generation of ROS strongly suggest that toxicity of HEC may be mediated through oxidative stress. This infers that the mechanism of biological response for MTT involves loss of an electron. But it must be remembered that the actual species used in the assays are the nitrate salts, which in solution, consist of the protonated form of the HEC and $[\text{NO}_3]^-$. Therefore, it is assumed that the biological mechanism of toxic response first involves loss of a proton to form the neutral HEC.

One of the aims of this study was to classify HEC based on mechanism of toxicity using an *in vitro* model. This would allow for the toxicity prediction of additional HEC proposed as new propellants or other applications and perhaps also provide insight into the biophysical mechanisms involved. The experimental results added to the hydrazine literature by demonstrating reduced mitochondrial function, increased LDH leakage, elevated ROS generation, and decreased GSH content at the end of 4-h exposures. There are number of reports available on hydrazine toxicity, however, there are no reports on toxicity of the HEC examined in this study. Hydrazine is known to deplete ATP, generate ROS and destabilize mitochondrial function (Kerai and Timbrell 1997). The results demonstrated that hydrazine-based compounds in general are more toxic than amine and triazole containing compounds. However, some chemicals displayed different toxicity; for example NAGN, although it belongs to hydrazine-based HEC, is a less toxic chemical. Similarly MAN which is an amine-based chemical and triazole-containing chemicals were relatively less toxic than other HEC based on the four toxicity end points tested. Based on these biochemical data, the chemicals were classified into three categories: higher toxicity (hydrazine containing compounds), medium toxicity (amino containing compounds), and lower toxicity (triazole containing compounds).

REFERENCES

- Anundi, I., Hogberg, J., and Stead, A.H. (1979). Glutathione depletion in isolated hepatocytes: Its relation to lipid peroxidation and cell damage. *Acta Pharmacol Toxicol (Copenh)*. 45 (1): 45-51.
- Bosan, W.S., Shank, R.C., MacEwen, J.D., Gaworski, C.L., and Newberne, P.M. (1987). Methylation of DNA guanine during the course of induction of liver cancer in hamsters by hydrazine or dimethylnitrosamine. *Carcinogenesis* 8 (3): 439-444.
- Carmichael, J., DeGraff, W.G., Gazdar, A.F., Minna, J.D., and Mitchell, J.B. (1987). Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. *Cancer Res.* 47: 936-942.
- Delaney J and Timbrell JA. (1995) Role of cytochrome P450 in hydrazine toxicity in isolated hepatocytes *in vitro*. *Xenobiotica*. 25:1399-410.
- DelRaso, N.J., and Frazier, J.M. (1999). Effect of culture conditions prior to exposure on cadmium cytotoxicity in primary rat hepatocytes. *Toxicol. Meth.* 9: 97-114.
- Farber, J.L., Kyle, M.E., and Coleman, J.B. (1990). Mechanisms of cell injury by activated oxygen species. *Lab Invest.* 62: 670-679.
- Ghatineh, S., Morgan, W., Preece, N.E., and Timbrell, J.A. (1992). A biochemical and NMR spectroscopic study of hydrazine in the isolated rat hepatocyte. *Arch. Toxicol.* 66: 660-668.

- Hussain, S., and Frazier, J. (2001). *In vitro* methods for toxicity assessment of high energy compounds. *Sci. Total Environ.* 274: 151-160.
- Hussain, S., Hass, B.S., Slikker, W., Jr, and Ali, S.F. (1999). Reduced levels of catalase activity potentiate MPP⁺-induced toxicity: comparison between MN9D cells and CHO cells. *Toxicol. Lett.* 104: 49-56.
- Jenner, A.M., and Timbrell, J.A. (1994). Influence of inducers and inhibitors of cytochrome P450 on the hepatotoxicity of hydrazine *in vivo*. *Arch. Toxicol.* 68(6): 349-357.
- Kaneo, Y., Iguchi, S., Kubo, H., Iwagiri, N., and Matsuyama, K. (1984). Tissue distribution of hydrazine and its metabolites in rats. *J. Pharmacobiodynamics* 7: 556-562.
- Kerai, M.D., and Timbrell, J.A. (1997). Effect of fructose on the biochemical toxicity of hydrazine in isolated rat hepatocytes. *Toxicol.* 120: 221-30.
- Kleineke, J., Peters, H., and Soling, H.D. (1979). Inhibition of hepatic gluconeogenesis by phenethylhydrazine (phenelzine). *Biochem. Pharmacol.* 28(8):1379-1389.
- Lightcap, E.S., Hopkins, M.H., Olson, G.T., Silverman, R.B., (1995). Time-dependent inhibition of gamma-aminobutyric acid aminotransferase, by 3-hydroxybenzylhydrazine. *Bioorg Med Chem.* 3: 579-85
- Loft, S., and Poulsen, H.E. (1999). Markers of oxidative damage to DNA: antioxidants and molecular damage. *Meth. Enzymol.* 300: 166-184.
- Moldeus, P., Hogberg, J. and Orrenius, S. (1978). Isolation and use of liver cells. *Meth. Enzymol.* 52: 60-72.
- Moloney, S.J., and Prough, R.A. (1983). Studies on the pathway of methane formation from procarbazine, a 2-methylbenzylhydrazine derivative, by rat liver microsomes. *Arch. Biochem. Biophys.* 221: 577-584.
- Preece, N.E., and Timbrell, J.A. (1989). Investigation of lipid peroxidation induced by hydrazine compounds *in vivo* in the rat. *Pharmacol. Toxicol.* 64: 282-285.
- Preece, N.E., Ghatineh, S., and Timbrell, J.A. (1990). Course of ATP depletion in hydrazine hepatotoxicity. *Arch. Toxicol.* 64: 49-53.
- Seglen, P.O. (1976). Preparation of isolated rat liver cells. *Meth. Cell Bio.* 3: 29-83.
- Sendo, T., Noda, A., Ohno, K., Goto, S., and Noda, H. (1984). Hepatotoxicity of hydrazine in isolated rat hepatocytes. *Chem. Pharm. Bull. (Tokyo)* 32: 795-796.
- Sies, H. (1999). Glutathione and its role in cellular functions. *Free Radical Biol. Med.* 27: 916-921.
- Tietze, F. (1969). Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. *Anal. Biochem.* 27(3): 502-522.
- Wakabayashi, T., Teranishi, M.A., Karbowski, M., Nishizawa, Y., Usukura, J., Kurono, C., and Soji, T. (2000). Functional aspects of megamitochondria isolated from hydrazine- and ethanol-treated rat livers. *Pathol. Int.* 50: 20-33.
- Wald, N., Boreham, J., Doll, R., and Bonsall, J. (1984). Occupational exposure to hydrazine and subsequent risk of cancer. *Br. J. Int. Med.* 41: 31-34.
- Wang, H., and Joseph, J.A. (1999). Quantitating cellular oxidative stress by dichlorofluorescein assay using microplate reader. *Free Radical Biol. Med.* 27: 612-616.
- Willis, J.E. (1966). The substitution of 1-methylhydrazine for ammonia in the glutamine synthetase system. *Biochem.* 11: 3557-3563.

IN VITRO RAT HEPATOCYTE TOXICITY AND BACTERIA GENOTOXICITY EVALUATION OF HIGH ENERGY CHEMICALS FOR REPLACEMENT OF HYDRAZINE

SECTION II. GENOTOXICITY ASSAYS FOR ELEVEN HIGH ENERGY COMPOUNDS: *SALMONELLA*/MICROSOME MUTAGENESIS ASSAY

Prepared by Sheela Sharma, Ph.D. and Pu Gao, M.D. (Cellular and Molecular Toxicology Program, Life Sciences and Toxicology Division, ManTech Environmental Technology, Inc., Research Triangle Park, NC), excerpted from Study No. 140-1126.

SUMMARY

The potential genotoxic effects of eleven high energy chemicals, HZN, DEHN, DHTN, DAGN, NAGN, EAN, HDN, MAN, TN, ATN and DMTN in *Salmonella*/Microsome mutagenicity assay (Ames Test) were investigated. In this assay, five bacterial strains (TA98, TA100, TA102, TA1535 and TA1537) were tested with and without the addition of activation system (S9). A modification of the standard plate incorporation method, the pre-incubation method was used to increase the sensitivity of the assay. The data from the range finding (dose selection) assay indicated that the concentrations used in the mutagenicity assay varied between chemicals for different strains. For example, 0.03-3.0 mg/plate were used for HZN (0.32-30 mM), DHTN (0.15-15 mM), NAGN (0.16-16 mM), MAN (0.27-27 mM) and DMTN (0.22-22mM); and 0.1-5.0 mg/plate were used for EAN (0.8-40 mM), HDN (0.42-21 mM), TN (0.75-38 mM) and ATN (0.67-34 mM), for all five strains. The concentrations for DAGN ranged from 0.03-3.0 mg/plate (0.2-2 mM) for tester strains TA100, TA102 and TA1535; and 0.1-5.0 mg/plate (0.54-32 mM) for strains TA98 and TA1537. Only range finding assay was performed for DEHN using tester strains TA98, TA100 and TA102, as there was a limited amount of chemical.

Results from the mutagenicity assay showed that, compared to the solvent control, HZN increased the revertants in TA102 and TA1535 in a dose-dependent manner at all concentrations tested (1.2-1.4 fold and 2.0-5.0 fold, respectively) in the presence of S9 activation system ($p < 0.05$). DHTN increased the revertants in three tester strains (TA98, TA100 and TA102) with and without S9 activation system at concentrations of 0.03-0.3 mg/plate (0.15-15 mM) ($p < 0.05$). Toxicity was observed at the highest concentrations (1 and 3 mg/plate or 5 and 15 mM) in all strains with significant increase in toxicity without S9. Unlike the effect in strains TA98 and TA102, DHTN showed a significant dose-dependent increase of revertants in TA100 in the presence of S9 (~2.0-4.0 fold). Similarly, in TA1535, DHTN also induced the mutant revertants in a dose-dependent manner at concentrations of 0.03-0.3 mg/plate (0.15-1.5 mM) with S9 (2.0-5.0 fold) and 0.03 and 0.1 mg/plate (0.15 and 0.5 mM) without S9 (~2 fold). MAN significantly increased (~5 fold) the revertants (non dose-dependent) in one tester strain (TA100) at all concentrations tested from 0.03-3.0 mg/plate (0.15-1.5 mM) with and without S9 activation system ($p < 0.01$). HDN and DMTN showed a moderate but statistically significant increase in the

revertants only in tester strain TA102 at all concentrations with and without S9 ($p < 0.05$). The concentrations of HDN that induced mutant revertants were 3.0-5.0 mg/plate with S9 and only 5.0 mg/plate (21 mM) without S9. The inducing concentrations for DMTN were 0.03-3.0 mg/plate (0.22-2.2 mM) with and without S9 activation system ($p < 0.05$). The rest of the compounds (DAGN, NAGN, EAN, TN and ATN) were negative in this assay.

The data from this study indicated that HZN, DHTN and MAN are mutagens in the bacterial system by causing both base pair substitutions (GC for TA100, AT for TA102) and frameshift (TA98) mutations. DHTN is a direct mutagen as there was no statistically significant increase in the number of histidine revertants in the activated (+S9) group compared to the non-activated (-S9) group in all three strains ($p > 0.05$). However, HZN and MAN can be considered as indirect mutagens, as there is a statistical difference in the number of histidine revertants between activated (+S9) group and non-activated (-S9) group ($p < 0.05$). Both HDN and DMTN appear to be weak mutagens in the bacterial system, although it showed statistically significant induction of revertants, however, the increase in revertant numbers did not reach the standard criteria of 2 fold increase.

INTRODUCTION

The overall objective of the study is to determine the potential genotoxicity associated with the exposure to eleven high energy chemicals (HZN, DEHN, DHTN, DAGN, NAGN, EAN, HDN, MAN, TN, ATN and DMTN), a new series of primarily hydrazine derivatives and amino-containing compounds with potential application as aircraft fuel and propellant to replace hydrazine, in *Salmonella*/Microsome mutagenicity assay (Ames Test). In a previous report, hydroxyethylhydrazinium nitrate (HEHN) elicited a positive mutagenic response in *Salmonella* strains TA102 and TA1535, but was negative in strains TA98, TA100, and TA1537 (Sharma and Gao, 1999). The *Salmonella*/mammalian microsome revertant mutation system is a well-defined short-term assay for the detection of carcinogens/mutagens. It measures the reversion from his⁻ (histidine dependent) to his⁺ (histidine independent) induced by chemicals that cause base changes or frameshift mutations in the genome of the organism. In this assay, bacteria are exposed to the test agent with and without a metabolic activation system (Aroclor 1254 induced rat liver S9 with co-factors) and plated onto minimal agar medium that is deficient in histidine. After incubation for 48 hours, revertant colonies are counted and compared with the number of spontaneous revertants in vehicle control culture. The mutagenicity of test agents is evident by the increase of revertants. All assays were conducted in accordance with the provision of the United States Environmental Protection Agency/Toxic Substances Control Acts (EPA/TSCA) Good Laboratory Practice (GLP) standards as defined in the Federal Register (40 CFR Part 792, 2002), the EPA/TSCA Health Effect Testing Guideline (40 CFR 798.5265, 2001-2002) and EPA Health Effects Test Guideline (OPPTS 870. 5100, 1998). All the procedures were performed in accordance with the Standard Operating Procedures (SOPs) of the Cellular and Molecular Toxicology Program at ManTech Environmental.

METHODS

Materials

Salmonella typhimurium strains

Five tester strains (TA98, TA100, TA102, TA1535 and TA1537) were obtained from Dr. Bruce N. Ames, Department of Molecular and Cell Biology, University of California at Berkeley (Ames *et al.*, 1975; Maron and Ames, 1983), stored at -80°C and used in this assay.

Metabolic activation system

Aroclor 1254-induced rat (Sprague-Dawley adult male) liver *S9 homogenate* (Cat # 11-101, Lot #1253 and 1289) was purchased from Moltax (Boone, N.C.), and stored at -80°C. It was diluted with cofactors to make the standard S9 activation mixture. The S9 mixture contains 33 mM KCl, 8 mM MgCl₂, 5 mM glucose-6-phosphate, 4 mM NADP and 100 mM phosphate buffer (pH 7.4) and S9 (0.04 mL/mL mixture). The concentration (volume) of S9 is based on the historical data from the laboratory and the revised methods for the *Salmonella* mutagenicity test by Maron and Ames (1983). The S9 mixture was made fresh prior to use and kept on ice.

Growth medium

Bacto nutrient broth (Difco Laboratories, Cat # 0003-17-8, Lot # 116525JD) was prepared by dissolving 8 g powder and 5 g NaCl in 1 L of distilled water, which was sterilized and used for growing tester strains. The growth medium was routinely stored at 4°C.

Top agar

Top agar contains 0.6% Bacto agar (Difco Laboratory, Cat # 0140-05, Control # 653470,781733 and 1274000) and 0.5 % NaCl in distilled water, which was autoclaved and stored at room temperature. Before plating, 10 mL of sterile 0.5 mM histidine/0.5 mM biotin solution was added to 100 mL of melted top agar, kept at 45°C and used as an overlay on the minimal agar plate.

Minimal agar plate

The minimal agar was prepared by dissolving 1.5% Bacto agar (Difco Laboratory, Cat # 0140-05, Control # 715860) and 2% glucose in Vogel-Bonner medium E. Minimal agar plates were made by adding 30 mL of the minimal glucose agar medium onto a 100-mm x 15-mm bacterial plate. Vogel-Bonner medium E was prepared by dissolving 0.04 M MgSO₄, 0.52 M citric acid, 2.87 M K₂HPO₄, and 0.87 M NaH₂NH₄ in distilled water and sterilized. It was stored at 4°C.

Chemicals for genotypes confirmation

Crystal violet (Fisher, Cat # C581, Lot # 870757): 0.1% dissolved in distilled water.

Histidine (Sigma, Cat # H-8125, Lot # 63H0202): 0.1 M dissolved in distilled water and sterilized.

Biotin (Sigma, Cat # B-4501, Lot # 34H0932): 0.5 M dissolved in distilled water and sterilized.

Ampicillin (Sigma, Cat # A-9518, Lot # 85H0372): 8 mg/mL dissolved in 0.02N NaOH.

Tetracycline (Sigma, Cat # T3383, Lot # 43H1092): 8 mg / mL dissolved in 0.02N HCl.

Positive control chemicals

2-Anthramine (Sigma, Cat # A1381, CAS # 613-13-8, Lot 3 77H1867): dissolved in DMSO, further diluted with DDH₂O to 25 µg/mL and 2.5 µg/plate was used for all five tester strains with S9 metabolic activation system.

9-Aminoacridine (Sigma, Cat # A-7295, CAS # 90-45-9, Lot # 106FO6681): dissolved in DMSO and further diluted with DDH₂O to 500 µg/mL and 50 µg/plate was used for tester strain TA1537 without S9 metabolic activation system.

Mitomycin C (Sigma, Cat # M0503, CAS # 50-07-7, Lot # 71F-0634): dissolved in DMSO, further diluted with DDH₂O to 5 µg/mL and 0.5 µg/plate was used for tester strain TA102 without S9 metabolic activation system.

2-Nitrofluorene (Aldrich, Cat # N 1,675-4, CAS # 607-57-8, Lot # ES02408LR): dissolved in DMSO and further diluted with DDH₂O to 100 µg/mL, and 10 µg/plate was used for tester strain TA98 without S9 metabolic activation system.

Sodium azide (Sigma, Cat # S-2002, CAS # 26628-22-8, Lot # 113H0265): dissolved in DMSO and further diluted with DDH₂O to 20 µg/mL, and 2 µg/plate was used for tester strains TA100 and TA1535 without S9 metabolic activation system.

Test agents

Test chemicals were directly obtained from Air Force Research Lab, Edwards Air Force Base, CA. HZN appeared as white solid particulate, DEHN, DAGN, NAGN, HDN, MAN, TA, ATN and DMTN appeared as white crystalline solid; DHTN appeared as amber-red crystalline solid and EAN appeared as colorless to white crystalline solid. The chemicals were kept at -80°C, pre-weighed in a glove-box for safety and dissolved in DMSO prior to use.

Procedures

Culturing of tester strains

The tester strains, frozen at -80°C were thawed, inoculated in nutrient broth and incubated in an environmental shaker incubator at 37°C for 12~15 hours to give the bacterial density of 1-2 x 10⁹/mL. The bacteria were kept in a refrigerator prior to use.

Genotype confirmation

Genotypes of each strain were confirmed prior to the mutagenesis study, which included the requirement of histidine (His⁻), the sensitivity to crystal violet (rfa mutation) and U.V. light (uvrB mutation), the resistance to ampicillin and tetracycline (R factor), ampicillin plus tetracycline for TA102 and ampicillin alone for the rest of four tester strains and the occurrence of spontaneous revertants.

Range-Finding Assay (Dose Selection)

A preliminary range-finding assay was performed using TA98, TA100 and TA102 or TA100 and TA102 to determine the optimal test concentrations for the mutagenesis assay. Five log concentrations (0.0005-5.0 mg/plate) of five chemicals (HZN, DEHN, DHTN, DAGN and EAN) were tested in TA98, TA100 and TA102; six (NAGN, HDN, MAN, TN, ATN and DMTN) were tested using TA100 and TA102 with modified standard plate incorporation, the pre-incubation method. All chemicals were dissolved in DMSO followed by four-log dilutions in DDH₂O, and no precipitation was observed in any of the chemical dilutions.

Mutagenesis Assay

Modified Standard Plate incorporation (pre-incubation method): In the mutagenesis assay, all chemicals were freshly dissolved in DMSO followed by four half log dilutions with DDH₂O prior to use, and no precipitation was observed.

For HZN, DHTN, NAGN, MAN and DMTN, 0.03-3.0 mg/plate were used in all five tester strains. For EAN, HDN, TN and ATN, 0.1-5.0 mg/plate were used in all five tester strains. For DAGN, the concentrations ranged from 0.03-3.0 mg/plate for tester strains TA100, TA102 and TA1535 and 0.1-5.0 mg/plate for tester strains TA98 and TA1537. Due to the limited amount of chemical, DEHN was tested only in the range-finding assay using tester strains TA98, TA100 and TA102.

One-tenth mL bacteria, 0.1 mL test agent and 0.5 mL S9 mixture (+S9 group) or 0.2 M phosphate buffer (-S9 group) were pre-incubated at 37°C for 20 min with shaking before 2 mL of top agar was added to this mixture. The contents were mixed, then poured onto the surface of a minimal glucose agar plate and spread out evenly. After the top agar was solidified, the plates were inverted and incubated at 37°C for 48 hours. The number of revertants per dish was counted by an automatic colony counter (AccuCount 1000, Biologics). The appearance of background lawn of bacterial growth was checked. Cultures were set up in triplicate; negative controls (spontaneous and solvent (DMSO) control) and positive controls were also included.

RESULTS

The raw data for the Ames Test are attached as Appendix A and the salient results are summarized as follows.

Genotype Identification

Different genotypes of the tester strains were verified by the standard procedure of B.N. Ames prior to the study. Results (see Table II-1) indicated that all the tester strains were qualified for the study.

TABLE II-1: GENOTYPE CONFIRMATION OF TESTER STRAINS

| Genotypes | TA98 | TA100 | TA102 | TA1535 | TA1537 |
|------------------------|----------|-----------|------------|----------|----------|
| Histidine requirement | + | + | + | + | + |
| rfa mutation | + | + | + | + | + |
| uvrB mutation | + | + | - | + | + |
| R factor | + | + | + | - | - |
| Spontaneous Revertants | 60 ± 3.8 | 150 ± 3.2 | 391 ± 11.7 | 17 ± 4.5 | 13 ± 4.7 |

Dose Selection for High Energy Chemicals

The conversion of mg/plate to mM concentration for each chemical in the dose selection assay is shown in Table II-2. The results from dose selection studies are listed in Tables II-3 through II-12. Based on the reduction compared to DMSO control revertants, toxicity was observed at 5 mg/plate for HZN, DHTN and DAGN in TA98, TA100 and TA102 and for NAGN in TA100 and TA102. Toxicity was noticed for MAN in TA100 at 5 mg/plate and slight toxicity in TA102 from 0.0005 to 0.5 mg/plate. TN showed a different toxicity pattern; 5 mg/plate was toxic only in S9-system in both TA100 and TA102. Similar toxicity pattern was noticed with DMTN in tester strain TA100 (toxicity only in the absence of S9 system). EAN and ATN were less toxic than the rest of the chemicals; either there was no toxicity or slight toxicity at all concentrations tested in all the tester strains. However, even when there was slight toxicity, no clearing of background lawn (indicating toxicity) was observed.

TABLE II-2: CONVERSION OF mg/PLATE TO mM CONCENTRATION FOR EACH CHEMICAL IN THE DOSE SELECTION ASSAY

| Chemical | MW | Dose selection (log dose) | |
|----------|--------|---------------------------|-----------|
| | | mg/plate | mM |
| HZN | 95.05 | 0.0005-5 | 0.0050-50 |
| DEHN | 151.16 | 0.0005-5 | 0.0030-30 |
| DHTN | 205.13 | 0.0005-5 | 0.0024-24 |
| DAGN | 152.11 | 0.0005-5 | 0.0032-32 |
| NAGN | 182.09 | 0.0005-5 | 0.0027-27 |
| EAN | 124.09 | 0.0005-5 | 0.0040-40 |
| HDN | 237.17 | 0.0005-5 | 0.0021-21 |
| MAN | 110.07 | 0.0005-5 | 0.0045-45 |
| TN | 132.08 | 0.0005-5 | 0.0037-37 |
| ATN | 147.09 | 0.0005-5 | 0.0033-33 |
| DMTN | 138.12 | 0.0005-5 | 0.0036-36 |

TABLE II-3: RESULTS OF DOSE SELECTION ASSAYS FOR HZN

| Treatment | TA98 | | TA100 | | TA102 | |
|----------------------------|-----------------|----------------|------------------|----------------|----------------|-----------------|
| | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | 37.89 ± 6.47 | 27.11 ± 6.54 | 141.22 ± 3.29 | 138.33 ± 8.50 | 350.78 ± 42.47 | 340.22 ± 23.31 |
| DMSO | 34.56 ± 6.27 | 27.89 ± 6.47 | 140.44 ± 15.07 | 137.78 ± 7.41 | 328.78 ± 31.65 | 358.22 ± 49.30 |
| Anthramine | 832.89 ± 160.84 | | 1285.33 ± 103.94 | | 518.78 ± 41.10 | |
| Mitomycin C | | | | | | 1592.78 ± 25.47 |
| 2-Nitrofluorene | | 151.22 ± 21.00 | | | | |
| Sodium azide | | | | 501.33 ± 31.97 | | |
| HZN (mg / plate) | | | | | | |
| 0.0005 | 40.78 ± 7.03 | 26.33 ± 6.17 | 157.22 ± 23.80 | 145.00 ± 11.79 | 417.22 ± 30.97 | 322.78 ± 23.05 |
| 0.005 | 39.22 ± 4.54 | 43.56 ± 11.03 | 133.67 ± 30.56 | 134.89 ± 8.01 | 539.44 ± 30.20 | 313.89 ± 15.94 |
| 0.05 | 29.89 ± 8.83 | 24.22 ± 5.50 | 141.78 ± 21.19 | 123.22 ± 13.93 | 401.22 ± 28.66 | 349.78 ± 26.65 |
| 0.5 | 30.67 ± 4.33 | 37.22 ± 5.36 | 158.33 ± 18.68 | 150.67 ± 10.59 | 545.78 ± 5.68 | 333.22 ± 11.01 |
| 5 | 2.00 ± 0.33 | 0.00 ± 0.00 | 30.44 ± 18.21 | 0.00 ± 0.00 | 83.67 ± 41.76 | 0.00 ± 0.00 |

TABLE II-4. RESULTS OF DOSE SELECTION ASSAYS FOR DEHN

| Treatment | TA98 | | TA100 | | TA102 | |
|----------------------|-----------------|----------------|-----------------|----------------|----------------|------------------|
| | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | 28.67 ± 2.65 | 21.44 ± 0.69 | 89.33 ± 20.27 | 138.67 ± 21.84 | 252.00 ± 32.62 | 270.67 ± 34.04 |
| DMSO | 28.56 ± 2.01 | 18.11 ± 4.00 | 63.33 ± 14.77 | 120.33 ± 27.84 | 201.56 ± 14.63 | 244.22 ± 9.58 |
| Anthramine | 1476.44 ± 56.40 | | 1362.56 ± 46.34 | | 496.44 ± 45.73 | |
| Mitomycin C | | | | | | 1342.67 ± 238.23 |
| 2-Nitrofluorene | | 482.11 ± 37.83 | | | | |
| Sodium azide | | | | 477.44 ± 77.30 | | |
| DEHN (mg / plate) | | | | | | |
| 0.0005 | 21.33 ± 4.67 | 26.78 ± 1.68 | 128.56 ± 29.41 | 135.33 ± 4.73 | 137.89 ± 46.74 | 163.33 ± 69.57 |
| 0.005 | 26.67 ± 2.52 | 27.11 ± 8.80 | 135.33 ± 39.70 | 103.00 ± 34.18 | 131.11 ± 8.37 | 221.67 ± 105.94 |
| 0.05 | 23.00 ± 2.91 | 23.22 ± 5.85 | 138.22 ± 33.01 | 119.33 ± 9.70 | 235.44 ± 64.95 | 229.00 ± 55.76 |
| 0.5 | 23.22 ± 3.10 | 17.89 ± 6.11 | 55.11 ± 15.83 | 84.56 ± 20.04 | 220.78 ± 82.10 | 300.89 ± 18.07 |
| 5 | 15.67 ± 3.21 | 24.11 ± 1.39 | 67.22 ± 19.17 | 105.67 ± 15.19 | 250.11 ± 31.67 | 271.67 ± 13.67 |

TABLE II-5: RESULTS OF DOSE SELECTION ASSAYS FOR DHTN

| Treatment | TA98 | | TA100 | | TA102 | |
|----------------------|------------------|----------------|------------------|-----------------|----------------|----------------|
| | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | 43.67 ± 5.77 | 24.33 ± 1.45 | 178.89 ± 16.10 | 196.44 ± 25.70 | 314.78 ± 30.52 | 273.67 ± 17.69 |
| DMSO | 48.67 ± 16.84 | 28.11 ± 3.02 | 142.00 ± 15.76 | 175.56 ± 6.62 | 284.11 ± 12.95 | 246.44 ± 14.79 |
| Anthramine | 1980.89 ± 191.10 | | 2202.44 ± 258.22 | | 344.00 ± 29.81 | |
| Mitomycin C | | | | | | 952.78 ± 96.27 |
| 2-Nitrofluorene | | 963.56 ± 60.75 | | | | |
| Sodium azide | | | | 597.56 ± 170.09 | | |
| DHTN (mg / plate) | | | | | | |
| 0.0005 | 27.78 ± 5.55 | 19.56 ± 4.30 | 106.11 ± 11.48 | 88.33 ± 9.68 | 318.78 ± 13.61 | 288.11 ± 66.55 |
| 0.005 | 16.44 ± 14.34 | 15.00 ± 12.99 | 115.33 ± 28.20 | 115.44 ± 20.57 | 408.89 ± 19.02 | 293.78 ± 25.82 |
| 0.05 | 44.44 ± 5.52 | 29.44 ± 4.35 | 157.11 ± 33.49 | 101.00 ± 50.02 | 434.78 ± 11.71 | 356.78 ± 7.24 |
| 0.5 | 18.67 ± 4.00 | 14.67 ± 3.48 | 0.00 ± 0.00 | 52.44 ± 90.84 | 509.89 ± 34.85 | 256.44 ± 14.38 |
| 5 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |

TABLE II-6: RESULTS OF DOSE SELECTION ASSAYS FOR DAGN

| Treatment | TA98 | | TA100 | | TA102 | |
|----------------------|------------------|----------------|------------------|-----------------|----------------|----------------|
| | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | 43.67 ± 5.77 | 24.33 ± 1.45 | 178.89 ± 16.10 | 196.44 ± 25.70 | 314.78 ± 30.52 | 273.67 ± 17.69 |
| DMSO | 48.67 ± 16.84 | 28.11 ± 3.02 | 142.00 ± 15.76 | 175.56 ± 6.62 | 284.11 ± 12.95 | 246.44 ± 14.79 |
| Anthramine | 1980.89 ± 191.10 | | 2202.44 ± 258.22 | | 344.00 ± 29.81 | |
| Mitomycin C | | | | | | 952.78 ± 96.27 |
| 2-Nitrofluorene | | 963.56 ± 60.75 | | | | |
| Sodium azide | | | | 597.56 ± 170.09 | | |
| DAGN (mg / plate) | | | | | | |
| 0.0005 | 20.89 ± 0.69 | 21.78 ± 0.84 | 128.89 ± 15.94 | 117.22 ± 11.72 | 310.56 ± 16.98 | 245.44 ± 51.09 |
| 0.005 | 29.33 ± 5.20 | 18.56 ± 6.26 | 128.33 ± 12.50 | 118.89 ± 8.23 | 291.33 ± 45.20 | 249.00 ± 4.67 |
| 0.05 | 39.00 ± 4.71 | 20.67 ± 3.84 | 87.78 ± 17.71 | 112.00 ± 7.33 | 286.44 ± 41.35 | 254.33 ± 27.65 |
| 0.5 | 16.67 ± 5.24 | 24.78 ± 8.70 | 131.22 ± 28.44 | 108.56 ± 1.95 | 296.89 ± 16.98 | 257.00 ± 19.86 |
| 5 | 9.00 ± 12.73 | 53.50 ± 39.36 | 0.00 ± 0.00 | 5.33 ± 9.24 | 197.44 ± 25.93 | 138.22 ± 12.06 |

TABLE II-7. RESULTS OF DOSE SELECTION ASSAYS FOR NAGN

| Treatment | TA100 | | TA102 | |
|----------------------|----------------|----------------|----------------|-----------------|
| | S9+ | S9- | S9+ | S9- |
| Spontaneous | 202.78 ± 12.33 | 184.33 ± 5.00 | 314.78 ± 30.52 | 273.67 ± 17.69 |
| DMSO | 162.44 ± 18.09 | 161.67 ± 24.67 | 284.11 ± 12.95 | 246.44 ± 14.79 |
| Anthramine | 898.22 ± 73.24 | | 344.00 ± 29.81 | |
| Mitomycin C | | | | 952.78 ± 96.27 |
| Sodium azide | | 525.33 ± 64.89 | | |
| NAGN (mg / plate) | | | | |
| 0.0005 | 177.56 ± 22.37 | 141.44 ± 17.02 | 320.56 ± 44.98 | 307.11 ± 8.57 |
| 0.005 | 179.22 ± 12.67 | 187.89 ± 7.83 | 365.78 ± 72.68 | 294.22 ± 8.49 |
| 0.05 | 205.11 ± 52.24 | 157.67 ± 8.54 | 311.33 ± 38.42 | 281.33 ± 13.04 |
| 0.5 | 147.11 ± 38.09 | 125.33 ± 15.07 | 295.22 ± 18.81 | 261.33 ± 16.19 |
| 5 | 61.56 ± 3.98 | 61.78 ± 42.47 | 110.67 ± 56.20 | 218.56 ± 326.87 |

TABLE II-8. RESULTS OF DOSE SELECTION ASSAYS FOR EAN

| Treatment | TA98 | | TA100 | | TA102 | |
|---------------------|-----------------|----------------|----------------|----------------|----------------|----------------|
| | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | 28.67 ± 2.65 | 21.44 ± 0.69 | 145.56 ± 31.89 | 125.00 ± 5.78 | 308.56 ± 16.27 | 311.00 ± 16.52 |
| DMSO | 28.56 ± 2.01 | 18.11 ± 4.00 | 113.89 ± 24.84 | 107.00 ± 24.06 | 325.89 ± 20.55 | 273.00 ± 9.24 |
| Anthramine | 1476.44 ± 56.40 | | 310.44 ± 58.22 | | 471.33 ± 68.31 | |
| Mitomycin C | | | | | | 797.22 ± 55.06 |
| 2-Nitrofluorene | | 482.11 ± 37.83 | | | | |
| Sodium azide | | | | 576.44 ± 81.08 | | |
| EAN (mg / plate) | | | | | | |
| 0.0005 | 28.44 ± 10.36 | 17.44 ± 7.40 | 107.78 ± 38.74 | 104.67 ± 9.71 | 261.56 ± 17.23 | 170.44 ± 13.00 |
| 0.005 | 31.11 ± 14.55 | 22.00 ± 4.10 | 309.44 ± 25.67 | 211.33 ± 11.02 | 95.22 ± 22.07 | 112.33 ± 4.93 |
| 0.05 | 76.89 ± 12.19 | 18.56 ± 2.36 | 352.44 ± 33.61 | 227.33 ± 10.17 | 104.33 ± 8.14 | 112.67 ± 14.11 |
| 0.5 | 47.56 ± 5.87 | 22.78 ± 7.65 | 325.67 ± 5.93 | 212.11 ± 14.34 | 93.78 ± 26.88 | 101.56 ± 4.34 |
| 5 | 74.56 ± 8.07 | 19.67 ± 3.38 | 349.89 ± 16.55 | 252.11 ± 34.58 | 85.89 ± 32.24 | 94.11 ± 15.64 |

TABLE II-9: RESULTS OF DOSE SELECTION ASSAYS FOR HDN

| Treatment | TA100 | | TA102 | |
|---------------------|----------------|----------------|----------------|-----------------|
| | S9+ | S9- | S9+ | S9- |
| Spontaneous | 118.89 ± 37.54 | 116.56 ± 13.80 | 319.33 ± 33.53 | 251.33 ± 45.21 |
| DMSO | 159.11 ± 26.46 | 89.78 ± 20.46 | 298.44 ± 19.47 | 207.89 ± 22.31 |
| Anthramine | 539.33 ± 51.52 | | 562.00 ± 21.50 | |
| Mitomycin C | | | | 1095.67 ± 22.98 |
| Sodium azide | | 364.67 ± 19.70 | | |
| HDN (mg / plate) | | | | |
| 0.0005 | 78.78 ± 6.94 | 91.22 ± 24.44 | 304.78 ± 52.86 | 237.78 ± 13.83 |
| 0.005 | 84.78 ± 36.85 | 85.33 ± 13.12 | 237.00 ± 53.70 | 232.78 ± 23.17 |
| 0.05 | 57.11 ± 20.77 | 134.33 ± 23.09 | 280.00 ± 26.10 | 276.67 ± 32.22 |
| 0.5 | 65.67 ± 13.62 | 77.44 ± 31.45 | 272.89 ± 16.69 | 237.78 ± 19.03 |
| 5 | 78.22 ± 17.72 | 83.22 ± 22.61 | 280.89 ± 64.36 | 270.56 ± 13.67 |

TABLE II-10: RESULTS OF DOSE SELECTION ASSAYS FOR MAN

| Treatment | TA100 | | TA102 | |
|---------------------|----------------|----------------|----------------|-----------------|
| | S9+ | S9- | S9+ | S9- |
| Spontaneous | 120.89 ± 39.90 | 116.56 ± 13.80 | 319.33 ± 33.53 | 240.22 ± 41.00 |
| DMSO | 159.11 ± 26.46 | 89.78 ± 20.46 | 298.44 ± 19.47 | 207.89 ± 22.31 |
| Anthramine | 539.33 ± 51.52 | | 562.00 ± 21.50 | |
| Mitomycin C | | | | 1095.67 ± 22.98 |
| Sodium azide | | 364.67 ± 19.70 | | |
| MAN (mg / plate) | | | | |
| 0.0005 | 50.56 ± 12.40 | 116.33 ± 18.41 | 233.00 ± 19.20 | 198.78 ± 11.03 |
| 0.005 | 97.78 ± 20.00 | 120.78 ± 21.49 | 237.00 ± 26.03 | 176.56 ± 11.13 |
| 0.05 | 91.78 ± 24.76 | 96.67 ± 30.55 | 226.78 ± 28.17 | 194.78 ± 30.16 |
| 0.5 | 127.67 ± 42.85 | 78.56 ± 8.49 | 217.11 ± 24.07 | 166.89 ± 24.05 |
| 5 | 7.89 ± 13.66 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |

TABLE II-11: RESULTS OF DOSE SELECTION ASSAYS FOR TN

| Treatment | TA100 | | TA102 | |
|--------------------|------------------|-----------------|----------------|----------------|
| | S9+ | S9- | S9+ | S9- |
| Spontaneous | 174.56 ± 28.25 | 160.33 ± 22.88 | 348.00 ± 11.50 | 287.78 ± 37.45 |
| DMSO | 150.89 ± 16.98 | 140.89 ± 8.57 | 254.22 ± 46.50 | 316.33 ± 38.48 |
| Anthramine | 1148.33 ± 201.68 | | 430.67 ± 26.26 | |
| Mitomycin C | | | | 985.22 ± 35.79 |
| Sodium azide | | 670.00 ± 124.38 | | |
| TN (mg / plate) | | | | |
| 0.0005 | 125.67 ± 4.26 | 155.78 ± 30.68 | 409.00 ± 11.85 | 343.33 ± 38.68 |
| 0.005 | 166.89 ± 2.80 | 172.33 ± 10.26 | 381.33 ± 42.61 | 379.67 ± 34.40 |
| 0.05 | 175.56 ± 16.20 | 159.78 ± 3.47 | 379.22 ± 40.82 | 313.00 ± 12.90 |
| 0.5 | 140.22 ± 24.09 | 158.89 ± 13.38 | 416.56 ± 9.71 | 341.22 ± 27.68 |
| 5 | 93.44 ± 9.31 | 15.22 ± 20.35 | 283.67 ± 54.62 | 64.00 ± 17.94 |

TABLE II-12. RESULTS OF DOSE SELECTION ASSAYS FOR ATN

| Treatment | TA100 | | TA102 | |
|---------------------|------------------|-----------------|----------------|----------------|
| | S9+ | S9- | S9+ | S9- |
| Spontaneous | 174.56 ± 28.25 | 160.33 ± 22.88 | 348.00 ± 11.50 | 287.78 ± 37.45 |
| DMSO | 150.89 ± 16.98 | 140.89 ± 8.57 | 254.22 ± 46.50 | 316.33 ± 38.48 |
| Anthramine | 1148.33 ± 201.68 | | 430.67 ± 26.26 | |
| Mitomycin C | | | | 985.22 ± 35.79 |
| Sodium azide | | 670.00 ± 124.38 | | |
| ATN (mg / plate) | | | | |
| 0.0005 | 149.00 ± 15.53 | 172.67 ± 10.17 | 342.00 ± 27.02 | 344.22 ± 35.30 |
| 0.005 | 141.67 ± 24.29 | 173.67 ± 15.41 | 387.89 ± 39.17 | 348.33 ± 9.33 |
| 0.05 | 176.89 ± 14.72 | 150.44 ± 8.92 | 377.33 ± 26.41 | 337.00 ± 15.31 |
| 0.5 | 143.56 ± 13.59 | 158.89 ± 17.83 | 392.56 ± 22.62 | 324.22 ± 33.97 |
| 5 | 95.00 ± 22.21 | 116.78 ± 143.52 | 373.89 ± 35.19 | 252.33 ± 73.96 |

TABLE II-13. RESULTS OF DOSE SELECTION ASSAYS FOR DMTN

| Treatment | TA100 | | TA102 | |
|----------------------|----------------|----------------|----------------|----------------|
| | S9+ | S9- | S9+ | S9- |
| Spontaneous | 145.56 ± 31.89 | 125.00 ± 5.78 | 308.56 ± 16.27 | 311.00 ± 16.52 |
| DMSO | 113.89 ± 24.84 | 107.00 ± 24.06 | 325.89 ± 20.55 | 273.00 ± 9.24 |
| Anthramine | 310.44 ± 58.22 | | 471.33 ± 68.31 | |
| Mitomycin C | | | | 797.22 ± 55.06 |
| Sodium azide | | 576.44 ± 81.08 | | |
| DMTN (mg / plate) | | | | |
| 0.0005 | 136.11 ± 87.81 | 92.33 ± 30.66 | 321.56 ± 18.63 | 206.00 ± 16.17 |
| 0.005 | 76.67 ± 2.03 | 108.44 ± 16.51 | 275.89 ± 28.57 | 232.44 ± 23.26 |
| 0.05 | 98.78 ± 12.36 | 112.89 ± 0.84 | 247.44 ± 24.65 | 222.56 ± 16.82 |
| 0.5 | 119.22 ± 50.80 | 88.00 ± 18.28 | 316.22 ± 11.33 | 243.00 ± 31.18 |
| 5 | 97.22 ± 25.38 | 0.00 ± 0.00 | 407.56 ± 8.85 | 307.44 ± 23.00 |

Mutagenicity Assay

The results of mutagenicity assay with five tester strains (TA98, TA100, TA102, TA1535, and TA1537) are summarized in Tables II-14 through II-23. The data are expressed as the average revertant number per plate from the triplicates. The results indicate that compared to the solvent control, HZN, DHTN, HDN, MAN, and DMTN increased revertant mutant numbers either at three, four or five concentrations.

HZN

HZN was tested from 0.03-3.0 mg/plate. At 3 mg/plate, toxicity was observed in TA98, TA100 and TA1537 with and without S9 system and in the case of TA102 and TA1535 without S9 activation system. Surprisingly, 1 mg/plate was toxic to all five strains without S9 activation system. HZN increased the mutant revertants in TA1535 in a dose-dependent manner with 2.0-5.0 fold induction in the presence of S9 activation system when compared to the DMSO control ($p < 0.01$). HZN also increased the revertants in TA102 at concentrations of 0.1-1.0 mg/plate with S9 activation system ($p < 0.05$). At 3 mg/plate, a slight decrease in revertant numbers was observed, probably because HZN was slightly toxic at this concentration. In addition, HZN revealed a toxic-related dose response in TA1535 in the absence of S9 activation system (Table II-14 and Figures II-1 and II-2).

DHTN

DHTN was tested at 0.03-3.0 mg/plate, and toxicity was observed at 1 and 3 mg/plate for all tester strains except TA102 with S9 system. DHTN increased the mutant revertants in four tester strains (TA98, TA100, TA102 and TA1535) with and without S9 activation system at concentrations of 0.03-0.3 mg/plate by 2.0-4.0 fold and 1.5-2.0 fold, respectively ($p < 0.05$) (Table II-15 and Figures II-3 and II-4).

HDN

HDN was tested at 0.1-5.0 mg/plate in all five strains; there was no toxicity in any of the concentrations tested. HDN showed a moderate but statistically significant increase of mutant revertants in tester strain TA102 at 3 and 5 mg/plate in the presence of S9 and 5 mg/plate in the absence of S9 ($p < 0.05$). However, the increase in revertant numbers did not reach the two fold induction criteria for this assay and is rated as a weak mutagen (Table II-16).

MAN

MAN was tested at 0.03-3.0 mg/plate, toxicity was observed at 3 mg/plate for tester strains TA98, TA102, TA1535 and TA1537 and there was no demonstrated induction of mutation. For tester strain TA100, there was toxicity in the absence of S9 system but not in the presence of S9 system at a concentration of 3 mg/plate. In the presence and absence of S9 system, there was a

highly significant increase of the mutant revertant numbers (non dose-dependent) at 0.03-3.0 mg/plate and 0.03-1.0 mg/plate by 4.4-4.6 fold and 3.3-4.5 fold, respectively ($p < 0.01$) (Table II-17 and Figure II-5).

DMTN

DMTN was tested at 0.03-3.0 mg/plate; there was no toxicity at all concentrations tested. DMTN increased the mutant revertants at 0.03-3.0 mg/plate in TA102 in both with and without S9 system. The increase in revertant numbers compared to solvent control was 1.3-1.4 and 1.4-1.6 fold, respectively. Although the increase did not reach the criteria for this assay (see above for HDN), it was still statistically significant ($p < 0.05$) and therefore DMTN can also be considered as a weak mutagen (Table II-18).

DAGN

DAGN was tested at 0.03-3.0 mg/plate for tester strains TA100, TA102 and TA1535, 0.1-5.0 mg/plate for TA98 and TA1537. There was toxicity at 3 mg/plate in TA100 and TA1535 without S9 system. Similarly, at 5 mg/plate, DAGN was toxic for TA98 without S9 system. There was no increase in mutant revertant numbers at any of the tested concentrations in all five strains (Table II-19).

NAGN

NAGN was tested at 0.03-3.0 mg/plate. Toxicity was seen at 3 mg/plate in TA100, TA102 and TA1535 without S9 system. The mutant revertant numbers were increased at 3 mg/plate in TA98 without S9 system. Since only one dose induced the mutation frequency, NAGN is classified as non mutagenic (Table II-20).

EAN

EAN was tested at 0.1-5.0 mg/plate. There was slight toxicity at 5 mg/plate for TA98 and TA100 with and without S9 system, and no mutagenicity observed at all tested concentrations in all five tester strains (Table II-21).

TN

TN was tested at 0.1-5.0 mg/plate. TN demonstrated toxicity at concentrations of 5 mg/plate for all tester strains in both with and without S9 system. At a concentration of 3 mg/plate, TN was toxic to all five strains without S9 system, and there was no increase in revertant numbers (Table II-22).

ATN

ATN was tested at concentrations of 0.1-5.0 mg/plate. At 5 mg/plate, toxicity was found in TA98 and TA1537 without S9 system; however, an increased number of revertants were observed with S9 system. In TA100, TA102, TA1535, and TA1537, ATN demonstrated toxicity in both systems at 5 mg/plate. At a concentration of 3 mg/plate, ATN was toxic to TA102 with S9 system and TA1535 without S9 system. A slight increase in the number of revertants was noticed in TA98 and TA1535 with S9 system and TA102 without S9 system. However, the induction of revertants did not show any dose response pattern or statistical significance ($p > 0.05$) (Table II-23).

DEHN

Due to the limited amount of chemical, only dose selection assay was performed for DEHN using three tester strains, TA98, TA100 and TA102. The data showed that DEHN was slightly toxic in TA100 at a dose of 0.5 and 5 mg/plate (Table II-3).

The experimental summary of 11 high energy chemicals is presented in Table II-24 (please note that there is no mutagenicity data for DEHN).

TABLE II-14: MUTAGENICITY ASSAY RESULTS OF HZN

| Treatment | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------------|----------------|----------------|------------------|-----------------|-----------------|----------------|----------------|----------------|---------------|----------------|
| | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | 21.89 ± 3.15 | 17.56 ± 0.51 | 113.67 ± 19.34 | 90.78 ± 10.94 | 188.33 ± 24.58 | 165.89 ± 15.88 | 8.00 ± 2.03 | 16.67 ± 2.33 | 10.89 ± 2.17 | 6.78 ± 1.71 |
| DMSO | 21.11 ± 1.39 | 19.78 ± 5.19 | 102.33 ± 9.94 | 114.00 ± 5.33 | 262.22 ± 8.03 | 233.67 ± 7.21 | 13.22 ± 2.27 | 12.00 ± 1.73 | 11.78 ± 1.26 | 8.89 ± 0.96 |
| Anthramine | 819.33 ± 31.15 | | 1160.89 ± 122.88 | | 650.89 ± 105.51 | | 182.11 ± 11.74 | | 206.44 ± 3.20 | |
| Aminoacridine | | | | | | | | | | 128.89 ± 13.93 |
| Mitomycin C | | | | | | 1313.11 ± 5.80 | | | | |
| 2-Nitrofluorene | | 380.00 ± 29.02 | | | | | | | | |
| Sodium azide | | | | 497.33 ± 121.10 | | | | 475.11 ± 24.05 | | |
| HZN (mg) (mM) | | | | | | | | | | |
| 0.03 0.32 | 27.33 ± 6.84 | 20.33 ± 5.77 | 125.33 ± 17.93 | 102.67 ± 8.35 | 255.44 ± 15.54 | 210.00 ± 14.15 | 28.78 ± 2.69 | 16.89 ± 3.67 | 8.67 ± 1.76 | 8.89 ± 1.26 |
| 0.1 1 | 26.00 ± 6.43 | 15.56 ± 3.36 | 124.22 ± 12.20 | 104.33 ± 5.21 | 289.89 ± 17.26 | 210.67 ± 11.55 | 45.11 ± 4.11 | 16.11 ± 3.34 | 9.56 ± 2.78 | 7.89 ± 3.02 |
| 0.3 3 | 27.67 ± 1.53 | 8.33 ± 2.33 | 132.56 ± 8.77 | 118.78 ± 12.21 | 323.89 ± 1.84 | 248.78 ± 24.41 | 60.22 ± 5.55 | 12.00 ± 2.65 | 8.44 ± 2.22 | 6.89 ± 0.84 |
| 1 10 | 20.67 ± 4.33 | 0.00 ± 0.00 | 136.56 ± 4.67 | 0.00 ± 0.00 | 347.11 ± 28.97 | 0.00 ± 0.00 | 76.67 ± 19.35 | 2.67 ± 1.15 | 11.56 ± 2.22 | 0.00 ± 0.00 |
| 3 30 | 8.78 ± 1.07 | 0.00 ± 0.00 | 46.78 ± 3.56 | 0.00 ± 0.00 | 206.67 ± 26.35 | 0.00 ± 0.00 | 40.33 ± 8.45 | 0.00 ± 0.00 | 6.11 ± 1.84 | 0.00 ± 0.00 |




Figure II-1: Mutant Revertants Induced by HZN in TA1535 with and without S9 Activation System




Figure II-2: Mutant Revertants Induced by HZN in TA102 with S9 Activation System

TABLE II-15: MUTAGENICITY ASSAY RESULTS OF DHTN

| Treatment | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------------|------------------|----------------|------------------|----------------|----------------|----------------|----------------|---------------|----------------|----------------|
| | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | 27.67 ± 13.17 | 33.44 ± 11.41 | 147.22 ± 19.79 | 154.11 ± 9.65 | 343.78 ± 18.96 | 252.56 ± 53.53 | 12.33 ± 2.40 | 11.56 ± 7.90 | 11.33 ± 1.45 | 12.22 ± 0.77 |
| DMSO | 31.78 ± 10.46 | 25.33 ± 4.04 | 132.11 ± 7.50 | 116.11 ± 17.48 | 277.22 ± 53.93 | 236.78 ± 21.99 | 8.89 ± 1.50 | 10.78 ± 3.86 | 16.00 ± 4.26 | 3.36 ± 3.36 |
| Anthramine | 1090.56 ± 155.50 | | 1780.00 ± 229.90 | | 619.78 ± 69.65 | | 193.22 ± 25.60 | | 325.78 ± 17.83 | |
| Aminoacridine | | | | | | | | | | 164.33 ± 53.26 |
| Mitomycin C | | | | | | 905.89 ± 69.28 | | | | |
| 2-Nitrofluorene | | 484.67 ± 21.30 | | | | | | | | |
| Sodium azide | .. | | | 702.67 ± 38.28 | | | | 530.22 ± 7.89 | | |
| DHTN (mg) | | | | | | | | | | |
| 0.03 | 66.56 ± 7.90 | 52.44 ± 11.18 | 251.11 ± 41.96 | 252.33 ± 20.58 | 425.44 ± 54.72 | 425.22 ± 26.10 | 18.56 ± 5.82 | 17.67 ± 3.93 | 13.78 ± 1.71 | 12.00 ± 3.84 |
| 0.1 | 52.89 ± 5.52 | 69.33 ± 3.84 | 447.33 ± 82.67 | 401.89 ± 84.96 | 517.56 ± 35.83 | 436.56 ± 22.04 | 28.78 ± 11.46 | 21.78 ± 6.52 | 13.67 ± 0.67 | 13.11 ± 4.17 |
| 0.3 | 51.78 ± 15.87 | 46.78 ± 4.34 | 488.78 ± 78.53 | 212.11 ± 39.12 | 495.22 ± 21.55 | 421.67 ± 41.06 | 43.56 ± 4.95 | 8.33 ± 3.48 | 13.67 ± 4.81 | 8.11 ± 1.64 |
| 1 | 15.56 ± 13.73 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 427.67 ± 12.86 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 15.22 ± 4.48 | 0.00 ± 0.00 |
| 3 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |




Figure II-3: Mutant Revertants Induced by DHTN in TA102 with and without S9 Activation System




Figure II-4: Mutant Revertants Induced by DHTN in TA1535 with and without S9 Activation System

TABLE II-16: MUTAGENICITY ASSAY RESULTS OF HDN

| Treatment | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------------|------------------|----------------|------------------|----------------|----------------|-----------------|---------------|----------------|---------------|----------------|
| | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | 58.56 ± 9.89 | 43.78 ± 2.14 | 153.00 ± 18.48 | 162.22 ± 10.08 | 356.78 ± 47.00 | 273.22 ± 24.62 | 13.22 ± 1.02 | 16.33 ± 1.67 | 10.33 ± 1.15 | 13.78 ± 4.17 |
| DMSO | 54.89 ± 8.04 | 38.33 ± 3.76 | 140.44 ± 34.00 | 156.89 ± 13.81 | 301.11 ± 24.69 | 260.33 ± 24.95 | 14.00 ± 1.20 | 16.11 ± 3.79 | 12.56 ± 5.05 | 13.33 ± 2.08 |
| Anthramine | 1293.89 ± 299.46 | | 1414.00 ± 169.75 | | 550.11 ± 83.05 | | 126.44 ± 8.13 | | 104.67 ± 3.48 | |
| Aminoacridine | | | | | | | | | | 109.00 ± 45.71 |
| Mitomycin C | | | | | | 1112.11 ± 28.47 | | | | |
| 2-Nitrofluorene | | 473.89 ± 23.82 | | | | | | | | |
| Sodium azide | | | 654.33 ± 27.50 | | | | | 595.44 ± 32.36 | | |
| HDN (mg) | | | | | | | | | | |
| 0.1 | 50.56 ± 3.67 | 39.44 ± 6.19 | 155.33 ± 3.28 | 143.33 ± 10.48 | 340.78 ± 11.80 | 269.00 ± 43.18 | 17.89 ± 3.40 | 15.67 ± 4.91 | 14.78 ± 6.19 | 10.89 ± 0.69 |
| 0.3 | 50.78 ± 8.32 | 35.33 ± 4.93 | 152.56 ± 19.25 | 151.78 ± 10.87 | 330.44 ± 63.84 | 290.56 ± 16.55 | 16.11 ± 6.54 | 14.22 ± 1.07 | 13.11 ± 5.17 | 11.89 ± 3.42 |
| 1 | 39.44 ± 5.17 | 34.33 ± 2.60 | 151.22 ± 12.51 | 150.89 ± 11.67 | 321.44 ± 49.38 | 258.56 ± 16.84 | 15.33 ± 0.33 | 12.78 ± 6.19 | 14.67 ± 4.51 | 10.44 ± 1.26 |
| 3 | 41.67 ± 4.16 | 45.11 ± 7.62 | 162.44 ± 15.33 | 162.22 ± 7.46 | 384.44 ± 16.58 | 267.33 ± 4.16 | 9.22 ± 1.02 | 14.22 ± 1.84 | 14.33 ± 0.33 | 12.78 ± 4.53 |
| 5 | 42.56 ± 6.50 | 36.33 ± 2.40 | 170.56 ± 14.38 | 161.00 ± 8.51 | 501.33 ± 12.55 | 398.00 ± 19.94 | 15.44 ± 4.35 | 12.67 ± 3.71 | 17.56 ± 2.41 | 9.00 ± 0.88 |

TABLE II-17: MUTAGENICITY ASSAY RESULTS OF MAN

| Treatment | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------------|----------------|----------------|-----------------|-----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | 38.11 ± 1.84 | 31.11 ± 2.99 | 107.11 ± 12.76 | 159.78 ± 38.72 | 323.44 ± 21.18 | 318.89 ± 10.99 | 15.33 ± 6.17 | 11.67 ± 4.06 | 14.22 ± 5.23 | 14.22 ± 3.24 |
| DMSO | 38.22 ± 10.69 | 31.44 ± 8.44 | 275.56 ± 33.76 | 241.78 ± 39.08 | 285.44 ± 29.25 | 246.67 ± 19.64 | 9.44 ± 1.17 | 11.00 ± 4.26 | 14.67 ± 5.29 | 10.56 ± 2.67 |
| Anthramine | 98.44 ± 140.99 | | 1260.00 ± 90.99 | | 389.22 ± 19.62 | | 105.00 ± 23.41 | | 147.67 ± 18.50 | |
| Aminoacridine | | | | | | | | | | 136.67 ± 43.92 |
| Mitomycin C | | | | | | 926.11 ± 61.48 | | | | |
| 2-Nitrofluorene | | 347.33 ± 20.22 | | | | | | | | |
| Sodium azide | | | | 944.33 ± 54.25 | | | | 579.78 ± 47.89 | | |
| MAN (mg) | | | | | | | | | | |
| 0.03 | 35.11 ± 7.76 | 32.00 ± 4.04 | 1279.89 ± 43.66 | 1047.78 ± 89.30 | 294.00 ± 91.00 | 269.00 ± 42.15 | 14.56 ± 2.12 | 9.56 ± 1.92 | 11.56 ± 4.07 | 8.89 ± 2.67 |
| 0.1 | 50.22 ± 12.22 | 42.78 ± 5.23 | 1226.22 ± 54.18 | 1047.56 ± 93.08 | 341.89 ± 3.56 | 249.00 ± 17.44 | 10.22 ± 2.71 | 7.33 ± 2.19 | 12.00 ± 1.00 | 10.56 ± 5.50 |
| 0.3 | 26.67 ± 5.49 | 29.78 ± 2.27 | 1249.44 ± 23.57 | 1087.67 ± 33.71 | 314.00 ± 21.11 | 286.33 ± 15.18 | 13.44 ± 7.49 | 13.56 ± 4.35 | 10.33 ± 2.85 | 10.44 ± 3.56 |
| 1 | 28.33 ± 3.79 | 24.22 ± 3.24 | 1278.78 ± 23.87 | 797.44 ± 32.15 | 268.89 ± 12.54 | 204.89 ± 26.70 | 22.78 ± 11.67 | 20.00 ± 6.23 | 6.33 ± 3.06 | 5.00 ± 4.84 |
| 3 | 2.67 ± 2.67 | 0.00 ± 0.00 | 1213.33 ± 15.70 | 32.67 ± 29.42 | 0.00 ± 0.00 | 0.00 ± 0.00 | 6.00 ± 3.76 | 0.00 ± 0.00 | 1.56 ± 1.39 | 2.11 ± 3.66 |




Figure II-5: Mutant Revertants Induced by MAN in TA100 with and without S9 Activation System

TABLE II-18: MUTAGENICITY ASSAY RESULTS OF DMTN

| Treatment | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------------|----------------|----------------|------------------|----------------|----------------|----------------|----------------|----------------|---------------|----------------|
| | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | 1.56 ± 0.96 | 32.00 ± 2.08 | 153.00 ± 18.48 | 162.22 ± 10.08 | 220.67 ± 16.38 | 189.33 ± 15.68 | 18.89 ± 7.24 | 14.22 ± 1.07 | 8.33 ± 3.18 | 10.33 ± 1.86 |
| DMSO | 36.78 ± 1.71 | 22.11 ± 0.84 | 140.44 ± 34.00 | 156.89 ± 13.81 | 268.78 ± 30.93 | 197.11 ± 36.72 | 16.67 ± 4.62 | 11.33 ± 2.33 | 11.89 ± 1.58 | 8.67 ± 2.33 |
| Anthramine | 868.00 ± 77.66 | | 1414.00 ± 169.75 | | 273.89 ± 20.60 | | 104.56 ± 28.59 | | 76.78 ± 25.71 | |
| Aminoacridine | | | | | | | | | | 107.33 ± 32.52 |
| Mitomycin C | | | | | | 895.00 ± 58.86 | | | | |
| 2-Nitrofluorene | | 586.67 ± 66.73 | | | | | | | | |
| Sodium azide | | | | 654.33 ± 27.50 | | | | 188.67 ± 20.33 | | |
| DMTN (mg) (mM) | | | | | | | | | | |
| 0.03 0.22 | 40.00 ± 9.26 | 37.44 ± 6.84 | 149.11 ± 3.15 | 164.00 ± 9.50 | 348.56 ± 60.63 | 308.00 ± 6.33 | 20.56 ± 8.00 | 15.44 ± 3.56 | 15.67 ± 8.33 | 11.44 ± 3.34 |
| 0.1 0.7 | 35.67 ± 7.69 | 46.78 ± 4.67 | 171.44 ± 10.03 | 151.33 ± 15.28 | 356.33 ± 24.67 | 284.78 ± 25.93 | 14.33 ± 3.93 | 13.00 ± 1.76 | 11.67 ± 5.33 | 10.33 ± 1.53 |
| 0.3 2.2 | 31.22 ± 2.67 | 43.00 ± 5.78 | 168.44 ± 13.50 | 155.22 ± 9.70 | 354.11 ± 24.35 | 291.56 ± 4.03 | 11.44 ± 3.98 | 13.11 ± 3.37 | 10.00 ± 1.20 | 11.44 ± 3.36 |
| 1 7 | 43.67 ± 5.20 | 50.22 ± 6.08 | 152.56 ± 7.24 | 157.22 ± 15.72 | 349.78 ± 57.58 | 294.33 ± 24.44 | 16.22 ± 4.74 | 11.11 ± 1.26 | 8.22 ± 0.96 | 10.22 ± 0.38 |
| 3 22 | 41.44 ± 4.67 | 39.67 ± 5.24 | 193.44 ± 10.51 | 109.00 ± 4.91 | 381.33 ± 52.85 | 332.33 ± 19.34 | 11.00 ± 3.93 | 9.67 ± 3.53 | 8.44 ± 2.22 | 8.89 ± 1.39 |

TABLE II-19: MUTAGENICITY ASSAY RESULTS OF DAGN

| Treatment | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------------|------------------|----------------|------------------|----------------|-----------------|----------------|----------------|--------------|----------------|----------------|
| | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | 54.33 ± 3.84 | 48.89 ± 4.55 | 200.33 ± 28.00 | 155.56 ± 8.77 | 220.78 ± 25.48 | 255.11 ± 28.01 | 22.11 ± 10.36 | 24.44 ± 5.42 | 18.33 ± 3.38 | 11.22 ± 4.25 |
| DMSO | 53.00 ± 10.04 | 38.89 ± 2.78 | 162.78 ± 11.65 | 146.89 ± 25.50 | 322.56 ± 44.89 | 239.22 ± 16.23 | 16.78 ± 1.84 | 20.33 ± 4.63 | 17.67 ± 5.51 | 15.44 ± 3.53 |
| Anthramine | 1547.00 ± 197.56 | | 1832.22 ± 153.61 | 414.33 ± 47.71 | | | 178.44 ± 18.47 | | 196.33 ± 45.00 | |
| Aminoacridine | | | | | | | | | | 210.67 ± 16.09 |
| Mitomycin C | | | | | | 716.56 ± 99.55 | | | | |
| 2-Nitrofluorene | | 782.44 ± 43.87 | | | | | | | | |
| Sodium azide | | | | 639.78 ± 55.23 | | | | | | 493.78 ± 9.35 |
| DAGN (mg) | (mM) | | | | | | | | | |
| 0.03 | 0.2 | | 179.33 ± 35.18 | 191.89 ± 33.13 | 168.33 ± 72.28 | 236.78 ± 47.23 | 11.22 ± 0.96 | 15.22 ± 1.84 | | |
| 0.1 | 0.54 | 58.33 ± 10.99 | 118.22 ± 31.48 | 163.78 ± 19.68 | 305.67 ± 105.69 | 285.33 ± 29.14 | 16.89 ± 4.48 | 14.11 ± 4.44 | 13.67 ± 4.04 | 12.00 ± 4.58 |
| 0.3 | 2.0 | 61.11 ± 5.75 | 116.33 ± 26.69 | 179.56 ± 30.65 | 333.89 ± 27.36 | 235.22 ± 63.27 | 14.56 ± 1.95 | 15.00 ± 0.00 | 12.00 ± 4.33 | 8.11 ± 2.50 |
| 1 | 5.4 | 44.67 ± 14.44 | 94.33 ± 5.61 | 148.89 ± 29.19 | 312.22 ± 32.27 | 296.00 ± 13.68 | 16.22 ± 4.55 | 17.00 ± 0.67 | 8.44 ± 0.84 | 8.67 ± 2.33 |
| 3 | 20 | 35.11 ± 4.00 | 125.11 ± 23.06 | 85.00 ± 102.50 | 267.56 ± 8.69 | 197.11 ± 28.77 | 20.89 ± 6.77 | 1.22 ± 2.12 | 15.78 ± 6.83 | 8.22 ± 2.27 |
| 5 | 32 | 28.11 ± 3.75 | 25.67 ± 0.58 | | | | | | 5.44 ± 0.51 | 0.00 ± 0.00 |

TABLE II-20: MUTAGENICITY ASSAY RESULTS OF NAGN

| Treatment | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------------|----------------|-----------------|------------------|----------------|----------------|-----------------|----------------|----------------|----------------|----------------|
| | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | 10.78 ± 2.83 | 32.67 ± 2.91 | 133.00 ± 14.88 | 140.67 ± 8.97 | 305.56 ± 23.43 | 274.56 ± 19.15 | 15.00 ± 3.53 | 12.67 ± 2.19 | 13.00 ± 2.33 | 8.67 ± 1.20 |
| DMSO | 10.44 ± 10.34 | 24.00 ± 5.24 | 136.56 ± 10.82 | 133.22 ± 3.67 | 316.22 ± 29.76 | 267.67 ± 32.26 | 12.56 ± 4.44 | 14.44 ± 1.35 | 9.11 ± 2.04 | 12.44 ± 1.54 |
| Anthramine | 121.33 ± 96.74 | | 1751.67 ± 194.01 | | 324.22 ± 39.17 | | 126.00 ± 17.64 | | 133.44 ± 25.93 | |
| Aminoacridine | | | | | | | | | | 151.11 ± 42.59 |
| Mitomycin C | | | | | | 1052.67 ± 52.34 | | | | |
| 2-Nitrofluorene | | 593.56 ± 103.26 | | | | | | | | |
| Sodium azide | | | | 786.44 ± 31.64 | | | | 746.67 ± 11.33 | | |
| NAGN (mg) | | | | | | | | | | |
| 0.03 | 18.00 ± 4.58 | 24.00 ± 5.77 | 147.67 ± 6.56 | 142.33 ± 11.15 | 312.78 ± 22.79 | 277.00 ± 10.97 | 11.78 ± 2.67 | 12.11 ± 5.19 | 7.56 ± 2.69 | 12.67 ± 1.33 |
| 0.1 | 12.89 ± 5.74 | 20.11 ± 4.79 | 140.56 ± 8.39 | 141.56 ± 1.26 | 315.33 ± 15.18 | 269.22 ± 14.73 | 13.00 ± 3.18 | 9.44 ± 2.50 | 10.89 ± 0.51 | 11.22 ± 2.91 |
| 0.3 | 13.67 ± 6.39 | 30.33 ± 8.02 | 137.89 ± 6.91 | 147.00 ± 18.67 | 317.33 ± 23.95 | 275.56 ± 20.38 | 12.67 ± 5.81 | 16.67 ± 6.98 | 16.44 ± 7.86 | 12.78 ± 3.17 |
| 1 | 12.00 ± 5.36 | 25.67 ± 3.53 | 127.11 ± 10.36 | 108.11 ± 9.64 | 319.11 ± 5.74 | 250.33 ± 29.02 | 12.44 ± 5.40 | 11.67 ± 4.63 | 11.56 ± 4.43 | 10.67 ± 1.20 |
| 3 | 29.22 ± 9.45 | 175.33 ± 97.06 | 126.11 ± 17.99 | 35.44 ± 40.54 | 299.78 ± 15.49 | 94.22 ± 20.67 | 14.89 ± 8.47 | 0.00 ± 0.00 | 7.67 ± 4.33 | 6.33 ± 1.53 |

TABLE II-21: MUTAGENICITY ASSAY RESULTS OF EAN

| Treatment | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | 22.78 ± 3.66 | 21.33 ± 6.03 | 121.22 ± 20.24 | 127.22 ± 4.72 | 288.56 ± 22.79 | 256.56 ± 19.55 | 18.78 ± 5.98 | 21.78 ± 7.38 | 12.89 ± 1.26 | 8.89 ± 2.83 |
| DMSO | 25.44 ± 2.99 | 25.56 ± 4.44 | 106.89 ± 7.32 | 105.22 ± 13.57 | 231.11 ± 36.22 | 250.67 ± 32.36 | 15.67 ± 2.91 | 14.33 ± 4.18 | 9.00 ± 0.33 | 8.67 ± 3.28 |
| Anthramine | 135.33 ± 77.95 | | 836.00 ± 47.76 | | 492.78 ± 19.35 | | 166.22 ± 26.27 | | 180.33 ± 34.18 | |
| Aminoacridine | | | | | | | | | | 183.22 ± 40.47 |
| Mitomycin C | | | | | | 918.22 ± 23.35 | | | | |
| 2-Nitrofluorene | | 502.33 ± 37.47 | | | | | | | | |
| Sodium azide | | | | 470.11 ± 53.50 | | | | 463.33 ± 13.74 | | |
| EAN (mg) (mM) | | | | | | | | | | |
| 0.1 | 26.33 ± 2.60 | 16.00 ± 4.04 | 124.89 ± 19.27 | 121.56 ± 10.65 | 272.56 ± 20.06 | 235.22 ± 39.58 | 23.44 ± 5.21 | 17.33 ± 5.84 | 13.00 ± 2.91 | 10.33 ± 2.33 |
| 0.3 | 32.00 ± 7.51 | 21.44 ± 1.84 | 123.78 ± 12.19 | 115.11 ± 12.62 | 264.00 ± 8.89 | 228.33 ± 40.78 | 24.44 ± 3.98 | 14.78 ± 3.02 | 9.22 ± 2.14 | 11.67 ± 7.02 |
| 1 | 32.11 ± 1.17 | 24.78 ± 4.74 | 115.89 ± 7.38 | 120.67 ± 6.81 | 286.00 ± 9.24 | 220.89 ± 23.57 | 16.22 ± 3.34 | 12.11 ± 2.55 | 9.00 ± 2.60 | 10.89 ± 0.77 |
| 3 | 27.11 ± 7.60 | 18.33 ± 3.06 | 117.67 ± 14.26 | 100.44 ± 8.34 | 215.00 ± 9.77 | 187.89 ± 17.39 | 22.22 ± 8.28 | 17.56 ± 4.29 | 9.67 ± 1.86 | 6.78 ± 0.51 |
| 5 | 22.22 ± 5.58 | 16.56 ± 0.77 | 105.56 ± 6.62 | 91.89 ± 11.48 | 278.67 ± 53.13 | 233.22 ± 33.10 | 23.56 ± 10.49 | 17.00 ± 7.94 | 12.89 ± 1.84 | 8.78 ± 2.50 |

TABLE II-22: MUTAGENICITY ASSAY RESULTS OF TN

| Treatment | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------------|-----------------|----------------|------------------|----------------|----------------|-----------------|----------------|----------------|----------------|----------------|
| | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | 44.67 ± 3.06 | 32.56 ± 4.02 | 156.44 ± 10.73 | 164.11 ± 5.68 | 348.11 ± 63.19 | 275.78 ± 20.66 | 11.11 ± 1.17 | 12.89 ± 0.69 | 14.11 ± 1.84 | 9.33 ± 3.48 |
| DMSO | 44.56 ± 4.30 | 25.22 ± 2.14 | 143.11 ± 20.64 | 150.22 ± 17.26 | 335.33 ± 5.51 | 276.44 ± 17.72 | 13.11 ± 4.88 | 13.56 ± 5.17 | 12.00 ± 0.88 | 8.00 ± 2.19 |
| Anthramine | 1149.56 ± 86.81 | | 1518.78 ± 194.51 | 604.33 ± 15.31 | | | 199.00 ± 20.88 | | 195.89 ± 20.44 | |
| Aminoacidine | | | | | | | | | | 182.00 ± 29.45 |
| Mitomycin C | | | | | | 1014.89 ± 10.51 | | | | |
| 2-Nitrofluorene | | 575.44 ± 22.97 | | | | | | | | |
| Sodium azide | | | | 756.78 ± 83.11 | | | | 642.22 ± 34.00 | | |
| TN (mg) (mM) | | | | | | | | | | |
| 0.1 | 33.00 ± 3.18 | 21.78 ± 1.84 | 162.67 ± 16.95 | 161.67 ± 6.00 | 341.33 ± 44.38 | 268.44 ± 6.74 | 8.56 ± 0.38 | 15.44 ± 3.15 | 9.78 ± 3.83 | 5.56 ± 1.64 |
| 0.3 | 41.11 ± 8.04 | 23.22 ± 7.12 | 169.44 ± 18.34 | 148.78 ± 4.40 | 325.00 ± 12.22 | 276.44 ± 19.02 | 13.11 ± 7.50 | 15.44 ± 6.35 | 8.11 ± 2.67 | 8.00 ± 4.48 |
| 1 | 44.11 ± 6.48 | 19.56 ± 7.50 | 165.00 ± 10.97 | 99.44 ± 14.85 | 321.78 ± 13.68 | 168.00 ± 10.48 | 8.56 ± 0.51 | 9.33 ± 4.26 | 10.78 ± 2.83 | 7.22 ± 0.84 |
| 3 | 34.56 ± 8.67 | 0.00 ± 0.00 | 132.67 ± 15.30 | 0.00 ± 0.00 | 284.56 ± 20.39 | 38.67 ± 2.73 | 7.44 ± 1.71 | 0.00 ± 0.00 | 12.89 ± 0.51 | 0.00 ± 0.00 |
| 5 | 5.44 ± 1.50 | 0.00 ± 0.00 | 61.11 ± 3.69 | 0.00 ± 0.00 | 39.00 ± 2.33 | 71.67 ± 7.64 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |

TABLE II-23: MUTAGENICITY ASSAY RESULTS OF ATN

| Treatment | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------------|-----------------|-----------------|------------------|----------------|----------------|----------------|---------------|----------------|---------------|----------------|
| | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | 77.67 ± 11.89 | 29.56 ± 6.19 | 153.00 ± 18.48 | 162.22 ± 10.08 | 248.11 ± 41.64 | 304.56 ± 38.79 | 8.56 ± 1.54 | 12.11 ± 3.66 | 8.00 ± 3.38 | 9.44 ± 3.75 |
| DMSO | 40.44 ± 3.01 | 27.11 ± 4.02 | 140.44 ± 34.00 | 156.89 ± 13.81 | 263.78 ± 22.71 | 261.67 ± 30.87 | 10.89 ± 2.59 | 12.00 ± 5.00 | 9.89 ± 4.48 | 6.67 ± 1.20 |
| Anthramine | 115.67 ± 108.38 | | 1414.00 ± 169.75 | | 456.89 ± 13.61 | | 229.11 ± 8.76 | | 223.44 ± 9.48 | |
| Aminoacridine | | | | | | | | | | 136.44 ± 18.86 |
| Mitomycin C | | | | | | 791.33 ± 68.06 | | | | |
| 2-Nitrofluorene | | 817.89 ± 102.42 | | | | | | | | |
| Sodium azide | | | | 654.33 ± 27.50 | | | | 655.33 ± 52.20 | | |
| ATN (mg) | | | | | | | | | | |
| 0.1 | 9.00 ± 1.33 | 24.44 ± 4.68 | 151.22 ± 27.27 | 138.67 ± 19.73 | 293.78 ± 15.70 | 259.89 ± 2.67 | 9.33 ± 1.33 | 16.56 ± 2.67 | 12.00 ± 0.88 | 10.89 ± 2.17 |
| 0.3 | 7.67 ± 4.18 | 33.11 ± 7.82 | 168.89 ± 23.12 | 155.67 ± 8.41 | 255.00 ± 13.50 | 256.89 ± 15.03 | 7.78 ± 0.51 | 11.33 ± 2.52 | 11.44 ± 0.84 | 11.56 ± 2.22 |
| 1 | 6.56 ± 0.69 | 30.89 ± 1.39 | 165.56 ± 13.50 | 135.67 ± 3.84 | 265.89 ± 6.59 | 223.33 ± 2.00 | 7.00 ± 1.45 | 4.78 ± 4.17 | 11.44 ± 2.50 | 8.89 ± 2.01 |
| 3 | 8.00 ± 19.92 | 32.89 ± 25.24 | 116.78 ± 39.50 | 91.44 ± 18.31 | 184.67 ± 7.00 | 230.22 ± 25.24 | 55.56 ± 25.13 | 0.00 ± 0.00 | 10.56 ± 3.72 | 6.44 ± 3.29 |
| 5 | 8.22 ± 23.25 | 0.00 ± 0.00 | 2.56 ± 4.43 | 0.00 ± 0.00 | 172.33 ± 33.39 | 85.22 ± 15.49 | 1.67 ± 1.53 | 0.00 ± 0.00 | 3.33 ± 0.58 | 0.00 ± 0.00 |

TABLE II-24: EXPERIMENTAL SUMMARY OF 11 HIGH ENERGY CHEMICALS

| Chemicals | Ames Test Toxicity | Mutagenicity | Site of Mutation | Strain # | Type of Mutation* |
|-----------|--------------------|-----------------------|----------------------------------|------------------------|-------------------|
| HZN | Moderate toxicity | Positive ^a | AT and GC base-pair substitution | TA102 and TA1535 | Indirect |
| DEHN | Moderate toxicity | NA** | | | |
| DHTN | Severe toxicity | Positive | AT and GC base-pair substitution | TA98, TA102 and TA1535 | Direct |
| DAGN | Minimal toxicity | Negative | frameshift mutation | | |
| NAGN | Minimal toxicity | Negative | | | |
| EAN | Minimal toxicity | Negative | | | |
| HDN | Minimal toxicity | Weak ^c | | | |
| MAN | Moderate toxicity | Moderate ^b | AT base - pair substitution | TA102 | Direct |
| TN | Moderate toxicity | Negative | GC base - pair substitution | TA100 | Indirect |
| ATN | Minimal toxicity | Negative | | | |
| DMTN | Minimal toxicity | Weak | AT base - pair substitution | TA102 | Direct |

* Indirect required S9 mixture for metabolic activation

** Only cose selection assay was performed

^aPositive: 1. Good dose response relationship
 2. More than one strain showed dose response relationship
 3. More than 2-fold induction

^bModerate: 1. Good dose response relationship
 2. Only one strain showed dose response relationship
 3. More than 2-fold induction

^cWeak: 1. No dose response relationship; at least two concentrations showed induction
 2. Only one strain showed a response
 3. Less than 2-fold induction

DISCUSSION

In this study, we tested ten hydrazine derivatives and amino-containing high energy compounds for their mutagenicity in bacterial system using the pre-incubation method recommended for nitro compounds, a selective and sensitive method.

In the dose selection assay, we used 5 mg/plate as top dose which is the maximum dose recommended by EPA's Office of Pollution Prevention and Toxics (OPPTs) health effects guideline. The dose selection data showed that HZN, DHTN, NAGN, MAN and DMTN were more toxic to the tester strains compared with DEHN, DAGN, EAN HDN and ATN. Therefore, the doses selected for the mutagenesis assay were 0.03-3.0 mg/plate for HZN, NAGN, DHTN, MAN, DMTN and 0.1-5.0 mg/plate for EAN, HDN, TN and ATN. In the case of DAGN, the test range was 0.03-3.0 mg/plate for TA100, TA102 and TA1535, 0.1-5.0 mg/plate for TA98 and TA1537. However, by using the above doses, HZN showed toxicity at 3 mg/plate, DHTN showed toxicity at 1 and 3 mg/plate, MAN and TN showed toxicity at 3.0 mg/plate. The other chemicals did not show any toxicity or slight toxicity in the mutagenesis assay. Combining the toxicity data from the two types of experiments (dose selection and mutagenicity), it was observed that the top dose (5 mg/plate, the maximum dose required for this assay) was extremely toxic. The ranking of agents based on toxicity is as follows: DHTN>HZN>MAN>TN>DEHN, DAGN, NAGN, EAN, HDN, ATN and DMTN.

The results from the mutagenesis assay indicated that HZN increased the revertants in TA102 and TA1535 with very good dose-dependent response in the presence of S9 system. The increase in the number of revertants was 1.2-1.4 fold and 2.0-5.0 fold, respectively, that of DMSO control. DHTN increased the revertants in TA98, TA100 and TA102 either in both with and without S9 activation system or without S9 system only (TA98). The increase in revertant numbers ranged from 1.5-3.7 fold compared with DMSO control. MAN significantly increased the revertants in TA100 with and without S9 activation system by 3.4-4.6 fold. HDN and DMTN slightly increased the numbers of revertants in TA102 at different concentrations. Among the five positive chemicals, four chemicals induced the mutant revertants in tester strain TA102, a strain that has AT base pair at the primary reversion site and has selected sensitivity to hydrazine compounds (Wilcox, 1990). In our previous study, hydroxyethylhydrazinium nitrate (HEHN, another hydrazine derivative) induced the revertants in TA102 and TA1535 with a very good dose response manner, and also increased the size of colonies in the TA1535 induced revertants (Sharma & Gao, 1999).

Interestingly, less toxicity was noticed in several chemicals at the high doses in the presence of S9 activation system compared with S9 negative system. It is possible that there is an increased detoxification of these compounds due to the presence of phase II enzymes that are present in the S9 fraction.

The above results under the experimental condition indicate that HZN, DHTN and MAN are mutagenic to bacteria, as it has caused an increase in the number of revertants in tester strains over three or more concentrations. Further, DHTN is a direct mutagen causing AT and GC base-pair substitutions and frameshift mutations as there was no difference in the numbers of revertants between the activated (S9+) and non-activated (S9-) group ($p > 0.05$). Furthermore, HZN and DHTN increased the revertants in multiple strains including the sensitive TA102 strain

with induction up to 4 fold. On the other hand, MAN, one of the amino compounds, induced the mutant revertants in TA100 only (and not in the sensitive strain, TA102). HZN and MAN are indirect mutagens, as there is a difference between S9+ and S9- group ($p < 0.05$). Finally, HDN and DMTN are considered weak mutagens, since the increased number of revertants did not reach the standard criteria of 2 fold increase over the solvent control, however, the induction of revertants is still considered statistically significant. An experimental summary of all tested chemicals is included in Table II-24.

REFERENCES

- Ames, B. N., J. Mccann, and E. Yamasaki (1975). Method for detecting carcinogens and mutagens with the *Salmonella*/mammalian-microsome mutagenicity test. *Mutation Res.* 31, 347-364.
- Brusick, D. (1994). In: *Principles and Methods of Toxicology, Third Edition*, A.W. Hayes Ed., Raven Press, NY, p545.
- Claxton, D. L., J. Allen, A. Auletta, K. Mortelmans, E. Nestmann and E. Zeiger (1987). Guide for the *Salmonella Typhimurium*/Mammalian Microsomal Test for bacterial mutagenicity. *Mutation Res.* 189, 83-91.
- Gatehouse, D., S. Haworth, T. Cebula, E. Gocke, L. Kier, T. Matsushima, C. Melcion, T. Nohmi, T. Ohta, S. Venitt and E. Zeiger (1994). Recommendations for the performance of bacterial mutation assays. *Mutation Res.* 312, 217-33.
- Maron, D. M, J. Katzenellenbogen and B. N. Ames (1981). Compatibility of organ solvents with the *Salmonella* /microsome test. *Mutation Res.* 88, 343-350.
- Maron, D. M. and B. N. Ames (1983). Revised methods for the *Salmonella* mutagenicity test. *Mutation Res.* 113, 173-215.
- Prival, M., S. J. Bell, V. D. Mitchell, M. D. Peiperl and V. L. Vaughan (1984). Mutagenicity of benzidine and benzidine-congener dyes and selected monoazo dyes in modified *Salmonella* assay. *Mutation Res.* 136, 33-47.
- Sharma, S. and Gao, P. (1999) Genotoxicity assays for hydroxyethylhydrazinium nitrate. *Salmonella*/Microsome Mutagenesis Assay. *A report for Toxic Hazard Research Unit, Study No. 1096-35F, Wright-Patterson Air Force Base, Dayton, OH. [AFRL/HEST Work Unit Number 7757A118 (currently 1710D413)]*
- Wilcox, P., A. Naidoo, D. J. Wedd and D. J. Gatehouse (1990). Comparison of *Salmonella Typhimurium* TA102 with *Escherichia Coli* WP2 tester strains. *Mutagenesis* 5, 285-91.
- Yahagi, T., M. Degawa, Y. Seino, T. Matsushima, M. Nagao, T. Sugimura and Y. Hashimoto (1975). Mutagenicity of carcinogenic azo dyes and their derivatives. *Cancer Letter* 1, 91-96.

-
2
APPENDIX II-A

Raw Data of *Salmonella* / Microsome Mutagenesis Assay

TABLE II-A1: MUTAGENICITY ASSAY RESULTS OF HZN

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|------------------|-------|--------|-------|---------|--------|--------|---------|--------|--------|--------|--------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | #2 | 23 | 18 | 131 | 83 | 161 | 167 | 10 | 14 | 11 | 5 |
| | #2 | 24 | 18 | 93 | 86 | 208 | 181 | 7 | 18 | 13 | 9 |
| | #3 | 18 | 17 | 117 | 103 | 197 | 149 | 7 | 18 | 9 | 6 |
| | Mean | 21.89 | 17.56 | 113.67 | 90.78 | 188.33 | 165.89 | 8.00 | 16.67 | 10.89 | 6.78 |
| | SD | 3.15 | 0.51 | 19.34 | 10.94 | 24.58 | 15.88 | 2.03 | 2.33 | 2.17 | 1.71 |
| DMSO | #2 | 21 | 20 | 92 | 119 | 266 | 228 | 15 | 10 | 13 | 10 |
| | #2 | 20 | 25 | 111 | 109 | 268 | 232 | 11 | 13 | 12 | 8 |
| | #3 | 23 | 14 | 104 | 114 | 253 | 242 | 14 | 13 | 10 | 8 |
| | Mean | 21.11 | 19.78 | 102.33 | 114.00 | 262.22 | 233.67 | 13.22 | 12.00 | 11.78 | 8.89 |
| | SD | 1.39 | 5.19 | 9.94 | 5.33 | 8.03 | 7.21 | 2.27 | 1.73 | 1.26 | 0.96 |
| Positive Control | #2 | 830 | 410 | 1232 | 358 | 756 | 1311 | 170 | 449 | 209 | 114 |
| | #2 | 844 | 352 | 1019 | 580 | 652 | 1320 | 184 | 481 | 207 | 141 |
| | #3 | 784 | 379 | 1232 | 554 | 545 | 1309 | 193 | 496 | 203 | 132 |
| | Mean | 819.33 | 380 | 1160.89 | 497.33 | 650.89 | 1313.11 | 182.11 | 475.11 | 206.44 | 128.89 |
| | SD | 31.15 | 29.02 | 122.88 | 121.1 | 105.51 | 5.8 | 11.74 | 24.05 | 3.2 | 13.93 |
| HZN (mg / plate) | #2 | 21 | 27 | 114 | 111 | 269 | 194 | 28 | 19 | 10 | 8 |
| | #2 | 34 | 17 | 116 | 103 | 259 | 218 | 26 | 19 | 7 | 8 |
| | #3 | 27 | 17 | 146 | 94 | 238 | 218 | 32 | 13 | 9 | 10 |
| | Mean | 27.33 | 20.33 | 125.33 | 102.67 | 255.44 | 210.00 | 28.78 | 16.89 | 8.67 | 8.89 |
| | SD | 6.84 | 5.77 | 17.93 | 8.35 | 15.54 | 14.15 | 2.69 | 3.67 | 1.76 | 1.26 |
| 0.1 | #2 | 33 | 12 | 111 | 102 | 303 | 197 | 50 | 12 | 7 | 11 |
| | #2 | 21 | 19 | 134 | 101 | 296 | 218 | 42 | 19 | 13 | 8 |
| | #3 | 23 | 16 | 128 | 110 | 270 | 217 | 44 | 17 | 9 | 5 |
| | Mean | 26.00 | 15.56 | 124.22 | 104.33 | 289.89 | 210.67 | 45.11 | 16.11 | 9.56 | 7.89 |
| | SD | 6.43 | 3.36 | 12.20 | 5.21 | 17.26 | 11.55 | 4.11 | 3.34 | 2.78 | 3.02 |
| 0.3 | #2 | 27 | 11 | 125 | 106 | 324 | 265 | 65 | 11 | 10 | 6 |
| | #2 | 26 | 7 | 131 | 130 | 326 | 221 | 62 | 10 | 9 | 7 |
| | #3 | 29 | 7 | 142 | 120 | 322 | 261 | 54 | 15 | 6 | 8 |
| | Mean | 27.67 | 8.33 | 132.56 | 118.78 | 323.89 | 248.78 | 60.22 | 12.00 | 8.44 | 6.89 |
| | SD | | | | | | | | | | |

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------|-------|-------|------|--------|-------|--------|-------|--------|------|--------|------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| 1 | SD | 1.53 | 2.33 | 8.77 | 12.21 | 1.84 | 24.41 | 5.55 | 2.65 | 2.22 | 0.84 |
| | #2 | 18 | 0 | 141 | 0 | 317 | 0 | 99 | 4 | 9 | 0 |
| | #2 | 18 | 0 | 132 | 0 | 350 | 0 | 65 | 2 | 13 | 0 |
| | #3 | 26 | 0 | 136 | 0 | 374 | 0 | 66 | 2 | 13 | 0 |
| | Mean | 20.67 | 0.00 | 136.56 | 0.00 | 347.11 | 0.00 | 76.67 | 2.67 | 11.56 | 0.00 |
| 3 | SD | 4.33 | 0.00 | 4.67 | 0.00 | 28.97 | 0.00 | 19.35 | 1.15 | 2.22 | 0.00 |
| | #2 | 8 | 0 | 51 | 0 | 177 | 0 | 37 | 0 | 6 | 0 |
| | #2 | 10 | 0 | 46 | 0 | 227 | 0 | 34 | 0 | 8 | 0 |
| | #3 | 8 | 0 | 44 | 0 | 216 | 0 | 50 | 0 | 4 | 0 |
| | Mean | 8.78 | 0.00 | 46.78 | 0.00 | 206.67 | 0.00 | 40.33 | 0.00 | 6.11 | 0.00 |
| | SD | 1.07 | 0.00 | 3.56 | 0.00 | 26.35 | 0.00 | 8.45 | 0.00 | 1.84 | 0.00 |

TABLE II-A-2: MUTAGENICITY ASSAY RESULTS OF DHTN

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | | |
|-------------------|-------|-----------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | |
| Spontaneous | #1 | 15 | 35 | 155 | 160 | 366 | 214 | 12 | 4 | 11 | 13 | |
| | #2 | 41 | 44 | 125 | 143 | 332 | 314 | 15 | 10 | 13 | 11 | |
| | #3 | 27 | 21 | 162 | 159 | 333 | 230 | 10 | 20 | 10 | 13 | |
| | Mean | 27.67 | 33.44 | 147.22 | 154.11 | 343.78 | 252.56 | 12.33 | 11.56 | 11.33 | 12.22 | |
| | SD | 13.17 | 11.41 | 19.79 | 9.65 | 18.96 | 53.53 | 2.40 | 7.90 | 1.45 | 0.77 | |
| | | #1 | 20 | 30 | 125 | 136 | 242 | 227 | 10 | 7 | 20 | 5 |
| DMSO | #2 | 35 | 25 | 132 | 111 | 250 | 262 | 7 | 14 | 17 | 8 | |
| | #3 | 40 | 22 | 140 | 102 | 339 | 222 | 9 | 11 | 11 | 12 | |
| | Mean | 31.78 | 25.33 | 132.11 | 116.11 | 277.22 | 236.78 | 8.89 | 10.78 | 16.00 | 8.11 | |
| | SD | 10.46 | 4.04 | 7.50 | 17.48 | 53.93 | 21.99 | 1.50 | 3.86 | 4.26 | 3.36 | |
| | | Anthramine | 1089 | 501 | 1768 | 743 | 635 | 985 | 222 | 526 | 344 | 107 |
| | | 2-Nitrofluorene | 1247 | 492 | 1556 | 697 | 680 | 858 | 173 | 539 | 308 | 175 |
| Positive Control | #3 | 936 | 461 | 2016 | 667 | 544 | 874 | 185 | 526 | 326 | 212 | |
| | Mean | 1090.56 | 484.67 | 1780 | 702.67 | 619.78 | 905.89 | 193.22 | 530.22 | 325.78 | 164.33 | |
| | SD | 155.5 | 21.3 | 229.9 | 38.28 | 69.65 | 69.28 | 25.6 | 7.89 | 17.83 | 53.26 | |
| | | Anthramine | 62 | 45 | 283 | 276 | 428 | 411 | 17 | 21 | 12 | 15 |
| | | Sodium azide | 76 | 47 | 266 | 242 | 479 | 455 | 14 | 19 | 13 | 13 |
| | | Mitomycin C | 62 | 65 | 204 | 239 | 369 | 409 | 25 | 13 | 16 | 8 |
| DHTN (rg / plate) | Mean | 66.56 | 52.44 | 251.11 | 252.33 | 425.44 | 425.22 | 18.56 | 17.67 | 13.78 | 12.00 | |
| | SD | 7.90 | 11.18 | 41.96 | 20.58 | 54.72 | 26.10 | 5.82 | 3.93 | 1.71 | 3.84 | |
| | | #1 | 48 | 73 | 418 | 332 | 553 | 424 | 23 | 15 | 14 | 17 |
| | | #2 | 59 | 69 | 541 | 378 | 518 | 462 | 42 | 22 | 14 | 13 |
| | | #3 | 52 | 66 | 383 | 496 | 482 | 424 | 22 | 28 | 13 | 9 |
| | | Mean | 52.89 | 69.33 | 447.33 | 401.89 | 517.56 | 436.56 | 28.78 | 21.78 | 13.67 | 13.11 |
| 0.1 | SD | 5.52 | 3.84 | 82.67 | 84.96 | 35.83 | 22.04 | 11.46 | 6.52 | 0.67 | 4.17 | |
| | | #1 | 70 | 47 | 578 | 227 | 492 | 400 | 39 | 4 | 12 | 7 |
| | | #2 | 44 | 42 | 456 | 168 | 476 | 469 | 49 | 11 | 19 | 7 |
| | | #3 | 41 | 51 | 432 | 241 | 518 | 396 | 42 | 10 | 10 | 10 |
| | | Mean | 51.78 | 46.78 | 488.78 | 212.11 | 495.22 | 421.67 | 43.56 | 8.33 | 13.67 | 8.11 |
| | | SD | | | | | | | | | | |

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | | |
|-----------|-------|-------|------|-------|-------|--------|-------|--------|------|--------|-------|------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | |
| 1 | SD | 15.87 | 4.34 | 78.53 | 39.12 | 21.55 | 41.06 | 4.95 | 3.48 | 4.81 | 1.64 | |
| | #1 | 0 | 0 | 0 | 0 | 440 | 0 | 0 | 0 | 20 | 0 | |
| | #2 | 26 | 0 | 0 | 0 | 414 | 0 | 0 | 0 | 12 | 0 | |
| | #3 | 21 | 0 | 0 | 0 | 429 | 0 | 0 | 0 | 13 | 0 | |
| | Mean | 15.56 | 0.00 | 0.00 | 0.00 | 427.67 | 0.00 | 0.00 | 0.00 | 0.00 | 15.22 | 0.00 |
| | SD | 13.73 | 0.00 | 0.00 | 0.00 | 12.86 | 0.00 | 0.00 | 0.00 | 0.00 | 4.48 | 0.00 |
| 3 | #1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | #2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | #3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | Mean | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| | SD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| | | | | | | | | | | | | |

TABLE II-A3: MUTAGENICITY ASSAY RESULTS OF HDN

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|------------------|--------|------------|-----------------|------------|--------------|------------|-------------|------------|--------------|------------|---------------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | #1 | 47 | 41 | 163 | 174 | 303 | 284 | 14 | 16 | 11 | 18 |
| | #2 | 66 | 45 | 164 | 155 | 392 | 290 | 12 | 15 | 9 | 10 |
| | #3 | 62 | 45 | 132 | 158 | 375 | 245 | 13 | 18 | 11 | 14 |
| | Mean | 58.56 | 43.78 | 153.00 | 162.22 | 356.78 | 273.22 | 13.22 | 16.33 | 10.33 | 13.78 |
| | SD | 9.89 | 2.14 | 18.48 | 10.08 | 47.00 | 24.62 | 1.02 | 1.67 | 1.15 | 4.17 |
| DMSO | #1 | 62 | 36 | 174 | 147 | 314 | 242 | 15 | 15 | 18 | 14 |
| | #2 | 46 | 36 | 106 | 173 | 317 | 251 | 13 | 20 | 10 | 11 |
| | #3 | 57 | 43 | 141 | 151 | 273 | 289 | 14 | 13 | 9 | 15 |
| | Mean | 54.89 | 38.33 | 140.44 | 156.89 | 301.11 | 260.33 | 14.00 | 16.11 | 12.56 | 13.33 |
| | SD | 8.04 | 3.76 | 34.00 | 13.81 | 24.69 | 24.95 | 1.20 | 3.79 | 5.05 | 2.08 |
| Positive Control | | Anthramine | 2-Nitrofluorene | Anthramine | Sodium azide | Anthramine | Mitomycin C | Anthramine | Sodium azide | Anthramine | Aminoacridine |
| | #1 | 1613 | 496 | 1220 | 648 | 646 | 1088 | 123 | 630 | 102 | 132 |
| | #2 | 1250 | 449 | 1537 | 684 | 501 | 1104 | 136 | 591 | 103 | 56 |
| | #3 | 1019 | 477 | 1485 | 630 | 503 | 1144 | 120 | 565 | 109 | 138 |
| | Mean | 1293.89 | 473.89 | 1414 | 654.33 | 550.11 | 1112.11 | 126.44 | 595.44 | 104.67 | 109 |
| SD | 299.46 | 23.82 | 169.75 | 27.5 | 83.05 | 28.47 | 8.13 | 32.36 | 3.48 | 45.71 | |
| HDJ (mg/plate) | | | | | | | | | | | |
| | 0.1 | #1 | 54 | 34 | 152 | 134 | 337 | 14 | 13 | 22 | 10 |
| | #2 | 47 | 46 | 158 | 155 | 354 | 309 | 20 | 13 | 13 | 12 |
| | #3 | 50 | 38 | 156 | 141 | 331 | 223 | 19 | 21 | 10 | 11 |
| | Mean | 50.56 | 39.44 | 155.33 | 143.33 | 340.78 | 269.00 | 17.89 | 15.67 | 14.78 | 10.89 |
| SD | 3.67 | 6.19 | 3.28 | 10.48 | 11.80 | 43.18 | 3.40 | 4.91 | 6.19 | 0.69 | |
| 0.3 | #1 | 41 | 32 | 155 | 142 | 277 | 305 | 12 | 15 | 13 | 9 |
| | #2 | 54 | 33 | 171 | 149 | 314 | 294 | 24 | 15 | 18 | 16 |
| | #3 | 57 | 41 | 132 | 164 | 401 | 273 | 12 | 13 | 8 | 11 |
| | Mean | 50.78 | 35.33 | 152.56 | 151.78 | 330.44 | 290.56 | 16.11 | 14.22 | 13.11 | 11.89 |
| | SD | 8.32 | 4.93 | 19.25 | 10.87 | 63.84 | 16.55 | 6.54 | 1.07 | 5.17 | 3.42 |
| 1 | #1 | 45 | 37 | 138 | 139 | 345 | 255 | 15 | 6 | 19 | 11 |
| | #2 | 39 | 33 | 154 | 163 | 265 | 277 | 16 | 17 | 14 | 11 |
| | #3 | 34 | 33 | 162 | 151 | 354 | 244 | 15 | 16 | 10 | 9 |
| | Mean | 39.44 | 34.33 | 151.22 | 150.89 | 321.44 | 258.56 | 15.33 | 12.78 | 14.67 | 10.44 |
| | SD | | | | | | | | | | |

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------|-------|-------|-------|--------|--------|--------|--------|--------|-------|--------|-------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| 3 | SD | 5.17 | 2.60 | 12.51 | 11.67 | 49.38 | 16.84 | 0.33 | 6.19 | 4.51 | 1.26 |
| | #1 | 43 | 49 | 146 | 156 | 386 | 263 | 10 | 14 | 15 | 10 |
| | #2 | 45 | 36 | 176 | 161 | 400 | 269 | 9 | 16 | 14 | 18 |
| | #3 | 37 | 50 | 165 | 170 | 367 | 271 | 8 | 12 | 14 | 10 |
| | Mean | 41.67 | 45.11 | 162.44 | 162.22 | 384.44 | 267.33 | 9.22 | 14.22 | 14.33 | 12.78 |
| 5 | SD | 4.16 | 7.62 | 15.33 | 7.46 | 16.58 | 4.16 | 1.02 | 1.84 | 0.33 | 4.53 |
| | #1 | 50 | 34 | 164 | 159 | 492 | 377 | 14 | 12 | 20 | 10 |
| | #2 | 40 | 38 | 160 | 170 | 496 | 417 | 12 | 9 | 16 | 8 |
| | #3 | 38 | 37 | 187 | 154 | 516 | 400 | 20 | 17 | 16 | 9 |
| | Mean | 42.56 | 36.33 | 170.56 | 161.00 | 501.33 | 398.00 | 15.44 | 12.67 | 17.56 | 9.00 |
| | SD | 6.50 | 2.40 | 14.38 | 8.51 | 12.55 | 19.94 | 4.35 | 3.71 | 2.41 | 0.88 |

TABLE II-A4: MUTAGENICITY ASSAY RESULTS OF MAN

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|------------------|-------|--------|--------|---------|---------|--------|--------|--------|--------|--------|--------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | #1 | 38 | 33 | 121 | 141 | 323 | 321 | 21 | 16 | 16 | 17 |
| | #2 | 36 | 28 | 97 | 134 | 303 | 329 | 9 | 9 | 8 | 15 |
| | #3 | 40 | 33 | 103 | 204 | 345 | 307 | 16 | 10 | 18 | 11 |
| | Mean | 38.11 | 31.11 | 107.11 | 159.78 | 323.44 | 318.89 | 15.33 | 11.67 | 14.22 | 14.22 |
| | SD | 1.84 | 2.99 | 12.76 | 38.72 | 21.18 | 10.99 | 6.17 | 4.06 | 5.23 | 3.24 |
| | | | | | | | | | | | |
| DMSO | #1 | 28 | 25 | 273 | 215 | 303 | 268 | 8 | 12 | 11 | 8 |
| | #2 | 37 | 28 | 311 | 287 | 302 | 243 | 11 | 15 | 13 | 10 |
| | #3 | 49 | 41 | 243 | 223 | 252 | 229 | 9 | 6 | 21 | 13 |
| | Mean | 38.22 | 31.44 | 275.56 | 241.78 | 285.44 | 246.67 | 9.44 | 11.00 | 14.67 | 10.56 |
| | SD | 10.69 | 8.44 | 33.76 | 39.08 | 29.25 | 19.64 | 1.17 | 4.26 | 5.29 | 2.67 |
| | | | | | | | | | | | |
| Positive Control | #1 | 439 | 368 | 1292 | 950 | 402 | 875 | 90 | 603 | 148 | 86 |
| | #2 | 650 | 346 | 1331 | 887 | 367 | 994 | 93 | 525 | 166 | 164 |
| | #3 | 707 | 328 | 1157 | 995 | 399 | 909 | 132 | 611 | 129 | 160 |
| | Mean | 598.44 | 347.33 | 1260 | 944.33 | 389.22 | 926.11 | 105 | 579.78 | 147.67 | 136.67 |
| | SD | 140.99 | 20.22 | 90.99 | 54.25 | 19.62 | 61.48 | 23.41 | 47.89 | 18.5 | 43.92 |
| | | | | | | | | | | | |
| MAN (mg / plate) | #1 | 30 | 31 | 1315 | 1106 | 294 | 238 | 13 | 11 | 11 | 12 |
| | #2 | 32 | 36 | 1294 | 1092 | 203 | 252 | 13 | 7 | 8 | 9 |
| | #3 | 44 | 28 | 1231 | 945 | 385 | 317 | 17 | 11 | 16 | 6 |
| | Mean | 35.11 | 32.00 | 1279.89 | 1047.78 | 294.00 | 269.00 | 14.56 | 9.56 | 11.56 | 8.89 |
| | SD | 7.76 | 4.04 | 43.66 | 89.30 | 91.00 | 42.15 | 2.12 | 1.92 | 4.07 | 2.67 |
| | | | | | | | | | | | |
| 0.1 | #1 | 64 | 49 | 1178 | 1095 | 346 | 257 | 13 | 7 | 11 | 17 |
| | #2 | 43 | 41 | 1285 | 1108 | 340 | 229 | 9 | 5 | 12 | 9 |
| | #3 | 43 | 39 | 1216 | 940 | 340 | 261 | 8 | 10 | 13 | 6 |
| | Mean | 50.22 | 42.78 | 1226.22 | 1047.56 | 341.89 | 249.00 | 10.22 | 7.33 | 12.00 | 10.56 |
| | SD | 12.22 | 5.23 | 54.18 | 93.08 | 3.56 | 17.44 | 2.71 | 2.19 | 1.00 | 5.50 |
| | | | | | | | | | | | |
| 0.3 | #1 | 23 | 32 | 1241 | 1126 | 301 | 270 | 7 | 17 | 13 | 13 |
| | #2 | 33 | 29 | 1276 | 1074 | 303 | 289 | 22 | 9 | 10 | 6 |
| | #3 | 24 | 28 | 1231 | 1063 | 338 | 300 | 12 | 15 | 8 | 12 |
| | Mean | 26.67 | 29.78 | 1249.44 | 1087.67 | 314.00 | 286.33 | 13.44 | 13.56 | 10.33 | 10.44 |
| | SD | | | | | | | | | | |
| | | | | | | | | | | | |

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------|-------|-------|-------|---------|--------|--------|--------|--------|-------|--------|------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| | SD | 5.49 | 2.27 | 23.57 | 33.71 | 21.11 | 15.18 | 7.49 | 4.35 | 2.85 | 3.56 |
| 1 | #1 | 31 | 27 | 1265 | 764 | 283 | 188 | 35 | 14 | 9 | 0 |
| | #2 | 24 | 25 | 1306 | 828 | 259 | 191 | 11 | 19 | 3 | 10 |
| | #3 | 30 | 21 | 1265 | 801 | 265 | 236 | 22 | 27 | 7 | 5 |
| | Mean | 28.33 | 24.22 | 1278.78 | 797.44 | 268.89 | 204.89 | 22.78 | 20.00 | 6.33 | 5.00 |
| | SD | 3.79 | 3.24 | 23.87 | 32.15 | 12.54 | 26.70 | 11.67 | 6.23 | 3.06 | 4.84 |
| 3 | #1 | 5 | 0 | 1208 | 63 | 0 | 0 | 4 | 0 | 3 | 0 |
| | #2 | 0 | 0 | 1201 | 5 | 0 | 0 | 10 | 0 | 2 | 6 |
| | #3 | 3 | 0 | 1231 | 30 | 0 | 0 | 4 | 0 | 0 | 0 |
| | Mean | 2.67 | 0.00 | 1213.33 | 32.67 | 0.00 | 0.00 | 6.00 | 0.00 | 1.56 | 2.11 |
| | SD | 2.67 | 0.00 | 15.70 | 29.42 | 0.00 | 0.00 | 3.76 | 0.00 | 1.39 | 3.66 |

TABLE II-A5: MUTAGENICITY ASSAY RESULTS OF DMTN

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|------------------|-------|-------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | #1 | 31 | 33 | 163 | 174 | 239 | 173 | 24 | 15 | 10 | 10 |
| | #2 | 31 | 34 | 164 | 155 | 209 | 205 | 22 | 13 | 10 | 12 |
| | #3 | 33 | 30 | 132 | 158 | 214 | 190 | 11 | 15 | 5 | 9 |
| | Mean | 31.56 | 32.00 | 153.00 | 162.22 | 220.67 | 189.33 | 18.89 | 14.22 | 8.33 | 10.33 |
| | SD | 0.96 | 2.08 | 18.48 | 10.08 | 16.38 | 15.68 | 7.24 | 1.07 | 3.18 | 1.86 |
| DMIO | #1 | 25 | 23 | 174 | 147 | 234 | 156 | 14 | 9 | 11 | 8 |
| | #2 | 26 | 22 | 106 | 173 | 292 | 209 | 22 | 14 | 14 | 11 |
| | #3 | 29 | 21 | 141 | 151 | 281 | 227 | 14 | 11 | 11 | 7 |
| | Mean | 26.78 | 22.11 | 140.44 | 156.89 | 268.78 | 197.11 | 16.67 | 11.33 | 11.89 | 8.67 |
| | SD | 1.71 | 0.84 | 34.00 | 13.81 | 30.93 | 36.72 | 4.62 | 2.33 | 1.58 | 2.33 |
| Positive Control | #1 | 843 | 511 | 1220 | 648 | 298 | 827 | 77 | 192 | 52 | 136 |
| | #2 | 806 | 610 | 1537 | 684 | 263 | 934 | 102 | 207 | 103 | 114 |
| | #3 | 955 | 638 | 1485 | 630 | 261 | 923 | 134 | 167 | 75 | 72 |
| | Mean | 868 | 586.67 | 1414 | 654.33 | 273.89 | 895 | 104.56 | 188.67 | 76.78 | 107.33 |
| | SD | 77.66 | 66.73 | 169.75 | 27.5 | 20.6 | 58.86 | 28.59 | 20.33 | 25.71 | 32.52 |
| DMTN (mg/ plate) | #1 | 45 | 32 | 147 | 164 | 402 | 303 | 29 | 12 | 6 | 12 |
| | #2 | 46 | 36 | 153 | 173 | 361 | 306 | 19 | 19 | 18 | 8 |
| | #3 | 29 | 45 | 148 | 154 | 283 | 315 | 14 | 15 | 22 | 15 |
| | Mean | 40.00 | 37.44 | 149.11 | 164.00 | 348.56 | 308.00 | 20.56 | 15.44 | 15.67 | 11.44 |
| | SD | 9.26 | 6.84 | 3.15 | 9.50 | 60.63 | 6.33 | 8.00 | 3.56 | 8.33 | 3.34 |
| 0.1 | #1 | 30 | 47 | 181 | 155 | 361 | 289 | 11 | 14 | 6 | 10 |
| | #2 | 33 | 42 | 161 | 135 | 330 | 257 | 13 | 11 | 17 | 12 |
| | #3 | 44 | 51 | 172 | 165 | 378 | 308 | 19 | 14 | 12 | 9 |
| | Mean | 35.67 | 46.78 | 171.44 | 151.33 | 356.33 | 284.78 | 14.33 | 13.00 | 11.67 | 10.33 |
| | SD | 7.69 | 4.67 | 10.03 | 15.28 | 24.67 | 25.93 | 3.93 | 1.76 | 5.33 | 1.53 |
| 0.3 | #1 | 54 | 47 | 173 | 154 | 326 | 295 | 10 | 17 | 10 | 8 |
| | #2 | 51 | 36 | 179 | 165 | 368 | 293 | 9 | 11 | 9 | 15 |
| | #3 | 49 | 46 | 153 | 146 | 368 | 287 | 16 | 11 | 11 | 11 |
| | Mean | 51.22 | 43.00 | 168.44 | 155.22 | 354.11 | 291.56 | 11.44 | 13.11 | 10.00 | 11.44 |
| | SD | | | | | | | | | | |

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------|-------|-------|-------|--------|--------|--------|--------|--------|-------|--------|-------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| 1 | SD | 2.67 | 5.78 | 13.50 | 9.70 | 24.35 | 4.03 | 3.98 | 3.37 | 1.20 | 3.36 |
| | #1 | 47 | 44 | 146 | 142 | 393 | 300 | 13 | 12 | 9 | 10 |
| | #2 | 38 | 51 | 160 | 174 | 284 | 268 | 22 | 12 | 8 | 11 |
| | #3 | 47 | 56 | 151 | 156 | 372 | 316 | 14 | 10 | 8 | 10 |
| | Mean | 43.67 | 50.22 | 152.56 | 157.22 | 349.78 | 294.33 | 16.22 | 11.11 | 8.22 | 10.22 |
| 3 | SD | 5.20 | 6.08 | 7.24 | 15.72 | 57.58 | 24.44 | 4.74 | 1.26 | 0.96 | 0.38 |
| | #1 | 38 | 41 | 196 | 106 | 424 | 353 | 10 | 7 | 9 | 9 |
| | #2 | 40 | 44 | 182 | 106 | 397 | 315 | 15 | 8 | 6 | 7 |
| | #3 | 47 | 34 | 203 | 115 | 322 | 329 | 8 | 14 | 10 | 10 |
| | Mean | 41.44 | 39.67 | 193.44 | 109.00 | 381.33 | 332.33 | 11.00 | 9.67 | 8.44 | 8.89 |
| | SD | 4.67 | 5.24 | 10.51 | 4.91 | 52.85 | 19.34 | 3.93 | 3.53 | 2.22 | 1.39 |

TABLE II-A6: MUTAGENICITY ASSAY RESULTS OF DAGN

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|------------------|-------|--------|--------|---------|--------|--------|--------|--------|--------|--------|--------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | #1 | 54 | 50 | 184 | 165 | 239 | 227 | 19 | 20 | 18 | 13 |
| | #2 | 58 | 53 | 233 | 148 | 232 | 256 | 34 | 23 | 22 | 14 |
| | #3 | 51 | 44 | 184 | 154 | 192 | 283 | 14 | 30 | 15 | 6 |
| | Mean | 54.33 | 48.89 | 200.33 | 155.56 | 220.78 | 255.11 | 22.11 | 24.44 | 18.33 | 11.22 |
| | SD | 3.84 | 4.55 | 28.00 | 8.77 | 25.48 | 28.01 | 10.36 | 5.42 | 3.38 | 4.25 |
| DMSD | #1 | 51 | 38 | 176 | 172 | 329 | 254 | 18 | 17 | 14 | 12 |
| | #2 | 44 | 37 | 160 | 147 | 275 | 222 | 15 | 18 | 15 | 16 |
| | #3 | 64 | 42 | 153 | 121 | 364 | 242 | 18 | 26 | 24 | 19 |
| | Mean | 53.00 | 38.89 | 162.78 | 146.89 | 322.56 | 239.22 | 16.78 | 20.33 | 17.67 | 15.44 |
| | SD | 10.04 | 2.78 | 11.65 | 25.50 | 44.89 | 16.23 | 1.84 | 4.63 | 5.51 | 3.53 |
| Positive Control | #1 | 1533 | 812 | 1662 | 588 | 455 | 602 | 185 | 492 | 210 | 216 |
| | #2 | 1357 | 804 | 1960 | 634 | 362 | 771 | 193 | 486 | 233 | 193 |
| | #3 | 1751 | 732 | 1875 | 698 | 427 | 777 | 158 | 504 | 146 | 224 |
| | Mean | 1547 | 782.44 | 1832.22 | 639.78 | 414.33 | 716.56 | 178.44 | 493.78 | 196.33 | 210.67 |
| | SD | 197.56 | 43.87 | 153.61 | 55.23 | 47.71 | 99.55 | 18.47 | 9.35 | 45 | 16.09 |
| DAGN (mg/plate) | #1 | | | 189 | 156 | 123 | 285 | 11 | 13 | | |
| | #2 | | | 209 | 221 | 252 | 234 | 12 | 15 | | |
| | #3 | | | 140 | 199 | 131 | 191 | 11 | 17 | | |
| | Mean | | | 179.33 | 191.89 | 168.33 | 236.78 | 11.22 | 15.22 | | |
| | SD | | | 35.18 | 33.13 | 72.28 | 47.23 | 0.96 | 1.84 | | |
| 0.1 | #1 | 53 | 48 | 153 | 181 | 184 | 255 | 22 | 16 | 17 | 13 |
| | #2 | 51 | 35 | 110 | 142 | 369 | 313 | 14 | 17 | 14 | 7 |
| | #3 | 71 | 29 | 92 | 168 | 364 | 289 | 15 | 9 | 9 | 16 |
| | Mean | 58.33 | 37.67 | 118.22 | 163.78 | 305.67 | 285.33 | 16.89 | 14.11 | 13.67 | 12.00 |
| | SD | 10.99 | 9.71 | 31.48 | 19.68 | 105.69 | 29.14 | 4.48 | 4.44 | 4.04 | 4.58 |
| 0.3 | #1 | 56 | 27 | 142 | 207 | 339 | 162 | 15 | 15 | 9 | 11 |
| | #2 | 60 | 39 | 118 | 147 | 304 | 276 | 12 | 15 | 10 | 7 |
| | #3 | 67 | 30 | 89 | 185 | 358 | 267 | 16 | 15 | 17 | 7 |
| | Mean | 61.11 | 32.00 | 116.33 | 179.56 | 338.89 | 235.22 | 14.56 | 15.00 | 12.00 | 8.11 |
| | SD | 5.75 | 6.57 | 26.69 | 30.65 | 27.36 | 63.27 | 1.95 | 0.00 | 4.33 | 2.50 |
| 1 | #1 | 61 | 60 | 101 | 148 | 277 | 310 | 17 | 18 | 8 | 11 |
| | #2 | 36 | 35 | 90 | 179 | 340 | 283 | 20 | 16 | 8 | 7 |
| | #3 | 37 | 44 | 92 | 120 | 320 | 295 | 11 | 17 | 9 | 8 |
| | Mean | 44.67 | 46.56 | 94.33 | 148.89 | 312.22 | 296.00 | 16.22 | 17.00 | 8.44 | 8.67 |

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------|-------|-------|-------|--------|-------|--------|--------|--------|------|--------|------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| 3 | SD | 14.44 | 12.69 | 5.61 | 29.19 | 32.27 | 13.68 | 4.55 | 0.67 | 0.84 | 2.33 |
| | #1 | 39 | 28 | 141 | 47 | 258 | 166 | 16 | 4 | 9 | 6 |
| | #2 | 35 | 36 | 136 | 7 | 271 | 202 | 29 | 0 | 16 | 10 |
| | #3 | 31 | 29 | 99 | 201 | 274 | 223 | 18 | 0 | 23 | 9 |
| | Mean | 35.11 | 31.00 | 125.11 | 85.00 | 267.56 | 197.11 | 20.89 | 1.22 | 15.78 | 8.22 |
| SD | 4.00 | 4.36 | 23.06 | 102.50 | 8.69 | 28.77 | 6.77 | 2.12 | 6.83 | 2.27 | |
| 5 | #1 | 29 | 26 | | | | | | | 5 | 0 |
| | #2 | 24 | 25 | | | | | | | 5 | 0 |
| | #3 | 31 | 26 | | | | | | | 6 | 0 |
| | Mean | 28.11 | 25.67 | | | | | | | 5.44 | 0.00 |
| | SD | 3.75 | 0.58 | | | | | | | 0.51 | 0.00 |

TABLE II-A-7: MUTAGENICITY ASSAY RESULTS OF NAGN

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|----------------------|-------|------------|-----------------|------------|--------------|------------|-------------|------------|--------------|------------|---------------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | #1 | 34 | 29 | 139 | 151 | 328 | 264 | 19 | 10 | 14 | 10 |
| | #2 | 30 | 34 | 116 | 138 | 308 | 263 | 14 | 13 | 15 | 9 |
| | #3 | 29 | 35 | 144 | 133 | 281 | 297 | 12 | 15 | 10 | 7 |
| | Mean | 30.78 | 32.67 | 133.00 | 140.67 | 305.56 | 274.56 | 15.00 | 12.67 | 13.00 | 8.67 |
| | SD | 2.83 | 2.91 | 14.88 | 8.97 | 23.43 | 19.15 | 3.53 | 2.19 | 2.33 | 1.20 |
| DMSC | #1 | 31 | 29 | 149 | 133 | 282 | 292 | 8 | 15 | 9 | 11 |
| | #2 | 41 | 25 | 129 | 137 | 336 | 231 | 14 | 16 | 11 | 13 |
| | #3 | 20 | 18 | 131 | 130 | 331 | 280 | 16 | 13 | 7 | 13 |
| | Mean | 30.44 | 24.00 | 136.56 | 133.22 | 316.22 | 267.67 | 12.56 | 14.44 | 9.11 | 12.44 |
| | SD | 10.34 | 5.24 | 10.82 | 3.67 | 29.76 | 32.26 | 4.44 | 1.35 | 2.04 | 1.54 |
| Positive: Control | | Anthramine | 2-Nitrofluorene | Anthramine | Sodium azide | Anthramine | Mitomycin C | Anthramine | Sodium azide | Anthramine | Aminoacridine |
| | #1 | 910 | 602 | 1912 | 820 | 365 | 1052 | 133 | 747 | 155 | 103 |
| | #2 | 1080 | 692 | 1807 | 757 | 287 | 1105 | 106 | 758 | 141 | 166 |
| | #3 | 1075 | 486 | 1536 | 783 | 320 | 1001 | 139 | 735 | 105 | 184 |
| | Mean | 1021.33 | 593.56 | 1751.67 | 786.44 | 324.22 | 1052.67 | 126 | 746.67 | 133.44 | 151.11 |
| SD | 96.74 | 103.26 | 194.01 | 31.64 | 39.17 | 52.34 | 17.64 | 11.33 | 25.93 | 42.59 | |
| NAGN (mg / plate) | | | | | | | | | | | |
| | #1 | 34 | 31 | 155 | 130 | 294 | 289 | 12 | 17 | 8 | 11 |
| | #2 | 43 | 21 | 142 | 151 | 338 | 273 | 14 | 13 | 5 | 14 |
| | #3 | 37 | 21 | 147 | 147 | 307 | 268 | 9 | 7 | 10 | 13 |
| | Mean | 38.00 | 24.00 | 147.67 | 142.33 | 312.78 | 277.00 | 11.78 | 12.11 | 7.56 | 12.67 |
| SD | 4.58 | 5.77 | 6.56 | 11.15 | 22.79 | 10.97 | 2.67 | 5.19 | 2.69 | 1.33 | |
| 0.1 | #1 | 31 | 15 | 148 | 143 | 332 | 255 | 11 | 12 | 11 | 14 |
| | #2 | 39 | 24 | 132 | 141 | 302 | 285 | 11 | 8 | 11 | 12 |
| | #3 | 28 | 22 | 142 | 141 | 313 | 268 | 17 | 8 | 10 | 8 |
| | Mean | 32.89 | 20.11 | 140.56 | 141.56 | 315.33 | 269.22 | 13.00 | 9.44 | 10.89 | 11.22 |
| | SD | 5.74 | 4.79 | 8.39 | 1.26 | 15.18 | 14.73 | 3.18 | 2.50 | 0.51 | 2.91 |
| 0.3 | #1 | 31 | 38 | 145 | 155 | 310 | 256 | 19 | 23 | 25 | 10 |
| | #2 | 41 | 22 | 132 | 160 | 298 | 297 | 10 | 18 | 16 | 16 |
| | #3 | 29 | 31 | 137 | 126 | 344 | 274 | 9 | 9 | 9 | 13 |
| | Mean | 33.67 | 30.33 | 137.89 | 147.00 | 317.33 | 275.56 | 12.67 | 16.67 | 16.44 | 12.78 |
| | SD | | | | | | | | | | |

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------|-------|-------|--------|--------|--------|--------|--------|--------|-------|--------|-------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| 1 | SD | 6.39 | 8.02 | 6.91 | 18.67 | 23.95 | 20.38 | 5.81 | 6.98 | 7.86 | 3.17 |
| | #1 | 31 | 24 | 124 | 110 | 324 | 225 | 9 | 9 | 17 | 12 |
| | #2 | 27 | 30 | 139 | 117 | 313 | 282 | 19 | 17 | 9 | 10 |
| | #3 | 38 | 23 | 119 | 98 | 321 | 244 | 10 | 9 | 9 | 10 |
| | Mean | 32.00 | 25.67 | 127.11 | 108.11 | 319.11 | 250.33 | 12.44 | 11.67 | 11.56 | 10.67 |
| 3 | SD | 5.36 | 3.53 | 10.36 | 9.64 | 5.74 | 29.02 | 5.40 | 4.63 | 4.43 | 1.20 |
| | #1 | 18 | 135 | 132 | 81 | 310 | 73 | 22 | 0 | 8 | 6 |
| | #2 | 35 | 105 | 106 | 3 | 307 | 115 | 6 | 0 | 3 | 5 |
| | #3 | 34 | 286 | 141 | 22 | 282 | 95 | 17 | 0 | 12 | 8 |
| | Mean | 29.22 | 175.33 | 126.11 | 35.44 | 299.78 | 94.22 | 14.89 | 0.00 | 7.67 | 6.33 |
| | SD | 9.45 | 97.06 | 17.99 | 40.54 | 15.49 | 20.67 | 8.47 | 0.00 | 4.33 | 1.53 |

TABLE II-A8: MUTAGENICITY ASSAY RESULTS OF EAN

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|------------------|-------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| Spontaneous | #1 | 19 | 22 | 113 | 133 | 270 | 267 | 26 | 13 | 12 | 11 |
| | #2 | 24 | 27 | 144 | 124 | 314 | 234 | 16 | 25 | 14 | 6 |
| | #3 | 26 | 15 | 107 | 125 | 282 | 269 | 15 | 27 | 12 | 10 |
| | Mean | 22.78 | 21.33 | 121.22 | 127.22 | 288.56 | 256.56 | 18.78 | 21.78 | 12.89 | 8.89 |
| | SD | 3.66 | 6.03 | 20.24 | 4.72 | 22.79 | 19.55 | 5.98 | 7.38 | 1.26 | 2.83 |
| DMSO | #1 | 27 | 31 | 103 | 93 | 270 | 215 | 19 | 14 | 9 | 10 |
| | #2 | 22 | 23 | 102 | 102 | 225 | 260 | 14 | 10 | 9 | 5 |
| | #3 | 27 | 23 | 115 | 120 | 198 | 277 | 14 | 19 | 9 | 11 |
| | Mean | 25.44 | 25.56 | 106.89 | 105.22 | 231.11 | 250.67 | 15.67 | 14.33 | 9.00 | 8.67 |
| | SD | 2.99 | 4.44 | 7.32 | 13.57 | 36.22 | 32.36 | 2.91 | 4.18 | 0.33 | 3.28 |
| Positive Control | #1 | 830 | 472 | 782 | 471 | 472 | 891 | 148 | 448 | 148 | 140 |
| | #2 | 760 | 490 | 855 | 416 | 510 | 930 | 154 | 473 | 216 | 190 |
| | #3 | 916 | 544 | 871 | 523 | 497 | 933 | 196 | 469 | 176 | 220 |
| | Mean | 835.33 | 502.33 | 836 | 470.11 | 492.78 | 918.22 | 166.22 | 463.33 | 180.33 | 183.22 |
| | SD | 77.95 | 37.47 | 47.76 | 53.5 | 19.35 | 23.35 | 26.27 | 13.74 | 34.18 | 40.47 |
| EAN (mg/plate) | #1 | 23 | 12 | 103 | 117 | 292 | 249 | 19 | 11 | 16 | 13 |
| | #2 | 28 | 20 | 137 | 134 | 274 | 266 | 29 | 23 | 11 | 9 |
| | #3 | 28 | 15 | 135 | 114 | 252 | 191 | 23 | 18 | 12 | 9 |
| | Mean | 26.33 | 16.00 | 124.89 | 121.56 | 272.56 | 235.22 | 23.44 | 17.33 | 13.00 | 10.33 |
| | SD | 2.60 | 4.04 | 19.27 | 10.65 | 20.06 | 39.58 | 5.21 | 5.84 | 2.91 | 2.33 |
| 0.3 | #1 | 36 | 23 | 112 | 112 | 257 | 249 | 26 | 16 | 8 | 18 |
| | #2 | 23 | 20 | 123 | 129 | 261 | 181 | 20 | 17 | 8 | 12 |
| | #3 | 36 | 21 | 136 | 104 | 274 | 254 | 28 | 11 | 12 | 4 |
| | Mean | 32.00 | 21.44 | 123.78 | 115.11 | 264.00 | 228.33 | 24.44 | 14.78 | 9.22 | 11.67 |
| | SD | 7.51 | 1.84 | 12.19 | 12.62 | 8.89 | 40.78 | 3.98 | 3.02 | 2.14 | 7.02 |
| 1 | #1 | 33 | 28 | 124 | 123 | 292 | 229 | 20 | 9 | 12 | 11 |
| | #2 | 32 | 19 | 111 | 113 | 291 | 194 | 13 | 13 | 8 | 11 |
| | #3 | 31 | 27 | 113 | 126 | 275 | 239 | 16 | 14 | 7 | 10 |
| | Mean | 32.11 | 24.78 | 115.89 | 120.67 | 286.00 | 220.89 | 16.22 | 12.11 | 9.00 | 10.89 |
| | SD | | | | | | | | | | |

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------|-------|-------|-------|--------|--------|--------|--------|--------|-------|--------|------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| 3 | SD | 1.17 | 4.74 | 7.38 | 6.81 | 9.24 | 23.57 | 3.34 | 2.55 | 2.60 | 0.77 |
| | #1 | 31 | 15 | 134 | 92 | 207 | 185 | 27 | 19 | 9 | 6 |
| | #2 | 32 | 21 | 111 | 100 | 226 | 172 | 13 | 21 | 8 | 7 |
| | #3 | 18 | 19 | 108 | 109 | 212 | 207 | 27 | 13 | 12 | 7 |
| | Mean | 27.11 | 18.33 | 117.67 | 100.44 | 215.00 | 187.89 | 22.22 | 17.56 | 9.67 | 6.78 |
| 5 | SD | 7.60 | 3.06 | 14.26 | 8.34 | 9.77 | 17.39 | 8.28 | 4.29 | 1.86 | 0.51 |
| | #1 | 19 | 17 | 98 | 98 | 217 | 271 | 17 | 11 | 13 | 6 |
| | #2 | 19 | 17 | 108 | 99 | 310 | 219 | 36 | 26 | 11 | 11 |
| | #3 | 29 | 16 | 110 | 79 | 308 | 209 | 18 | 14 | 15 | 9 |
| | Mean | 22.22 | 16.56 | 105.56 | 91.89 | 278.67 | 233.22 | 23.56 | 17.00 | 12.89 | 8.78 |
| | SD | 5.58 | 0.77 | 6.62 | 11.48 | 53.13 | 33.10 | 10.49 | 7.94 | 1.84 | 2.50 |

TABLE II-A9: MUTAGENICITY ASSAY RESULTS OF TN

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | | |
|------------------|-------|---------|--------|---------|--------|--------|---------|--------|--------|--------|-------|---|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | |
| Spontaneous | #1 | 48 | 33 | 166 | 159 | 412 | 252 | 11 | 14 | 12 | 13 | |
| | #2 | 44 | 28 | 145 | 170 | 286 | 284 | 12 | 12 | 16 | 7 | |
| | #3 | 42 | 36 | 159 | 164 | 346 | 291 | 10 | 13 | 14 | 8 | |
| | Mean | 44.67 | 32.56 | 156.44 | 164.11 | 348.11 | 275.78 | 11.11 | 12.89 | 14.11 | 9.33 | |
| | SD | 3.06 | 4.02 | 10.73 | 5.68 | 63.19 | 20.66 | 1.17 | 0.69 | 1.84 | 3.48 | |
| | | #1 | 41 | 24 | 156 | 166 | 341 | 256 | 12 | 8 | 12 | 8 |
| DMSD | #2 | 43 | 28 | 119 | 132 | 330 | 287 | 9 | 17 | 11 | 10 | |
| | #3 | 49 | 24 | 154 | 152 | 336 | 286 | 18 | 16 | 13 | 6 | |
| | Mean | 44.56 | 25.22 | 143.11 | 150.22 | 335.33 | 276.44 | 13.11 | 13.56 | 12.00 | 8.00 | |
| | SD | 4.30 | 2.14 | 20.64 | 17.26 | 5.51 | 17.72 | 4.88 | 5.17 | 0.88 | 2.19 | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Positive Control | #1 | 1087 | 550 | 1597 | 663 | 593 | 1006 | 201 | 676 | 178 | 216 | |
| | #2 | 1249 | 582 | 1297 | 786 | 599 | 1026 | 177 | 642 | 191 | 164 | |
| | #3 | 1113 | 595 | 1662 | 821 | 622 | 1013 | 219 | 608 | 218 | 166 | |
| | Mean | 1149.56 | 575.44 | 1518.78 | 756.78 | 604.33 | 1014.89 | 199 | 642.22 | 195.89 | 182 | |
| | SD | 86.81 | 22.97 | 194.51 | 83.11 | 15.31 | 10.51 | 20.88 | 34 | 20.44 | 29.45 | |
| | | | | | | | | | | | | |
| TN (mg plate) | #1 | 35 | 23 | 181 | 162 | 388 | 261 | 9 | 13 | 10 | 4 | |
| | #2 | 29 | 20 | 160 | 168 | 336 | 272 | 8 | 19 | 14 | 6 | |
| | #3 | 35 | 23 | 147 | 156 | 300 | 272 | 8 | 14 | 6 | 7 | |
| | Mean | 33.00 | 21.78 | 162.67 | 161.67 | 341.33 | 268.44 | 8.56 | 15.44 | 9.78 | 5.56 | |
| | SD | 3.18 | 1.84 | 16.95 | 6.00 | 44.38 | 6.74 | 0.38 | 3.15 | 3.83 | 1.64 | |
| | | #1 | 39 | 18 | 162 | 144 | 338 | 258 | 13 | 22 | 8 | 4 |
| 0.3 | #2 | 50 | 31 | 190 | 153 | 314 | 296 | 21 | 9 | 11 | 13 | |
| | #3 | 34 | 20 | 156 | 150 | 322 | 275 | 6 | 15 | 5 | 7 | |
| | Mean | 41.11 | 23.22 | 169.44 | 148.78 | 325.00 | 276.44 | 13.11 | 15.44 | 8.11 | 8.00 | |
| | SD | 8.04 | 7.12 | 18.34 | 4.40 | 12.22 | 19.02 | 7.50 | 6.35 | 2.67 | 4.48 | |
| | | #1 | 37 | 14 | 159 | 85 | 329 | 156 | 9 | 10 | 8 | 6 |
| | 1 | #2 | 50 | 17 | 178 | 115 | 330 | 173 | 9 | 13 | 11 | 7 |
| #3 | | 46 | 28 | 159 | 99 | 306 | 175 | 8 | 5 | 14 | 8 | |
| Mean | | 44.11 | 19.56 | 165.00 | 99.44 | 321.78 | 168.00 | 8.56 | 9.33 | 10.78 | 7.22 | |
| SD | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | | |
|-----------|-------|-------|------|--------|-------|--------|-------|--------|------|--------|-------|------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | |
| 3 | SD | 6.48 | 7.50 | 10.97 | 14.85 | 13.68 | 10.48 | 0.51 | 4.26 | 2.83 | 0.84 | |
| | #1 | 26 | 0 | 150 | 0 | 304 | 36 | 6 | 0 | 13 | 0 | |
| | #2 | 34 | 0 | 124 | 0 | 286 | 41 | 9 | 0 | 12 | 0 | |
| | #3 | 43 | 0 | 124 | 0 | 263 | 39 | 7 | 0 | 13 | 0 | |
| | Mean | 34.56 | 0.00 | 132.67 | 0.00 | 284.56 | 38.67 | 7.44 | 0.00 | 0.00 | 12.89 | 0.00 |
| | SD | 8.67 | 0.00 | 15.30 | 0.00 | 20.39 | 2.73 | 1.71 | 0.00 | 0.00 | 0.51 | 0.00 |
| 5 | #1 | 7 | 0 | 65 | 0 | 38 | 78 | 0 | 0 | 0 | 0 | |
| | #2 | 5 | 0 | 61 | 0 | 42 | 73 | 0 | 0 | 0 | 0 | |
| | #3 | 4 | 0 | 58 | 0 | 37 | 63 | 0 | 0 | 0 | 0 | |
| | Mean | 5.44 | 0.00 | 61.11 | 0.00 | 39.00 | 71.67 | 0.00 | 0.00 | 0.00 | 0.00 | |
| | SD | 1.50 | 0.00 | 3.69 | 0.00 | 2.33 | 7.64 | 0.00 | 0.00 | 0.00 | 0.00 | |

TABLE II-A10: MUTAGENICITY ASSAY RESULTS OF ATN

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | | |
|------------------|-------|---------|--------|--------|--------|--------|--------|--------|--------|--------|--------|---|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | |
| Spontaneous | #1 | 51 | 36 | 163 | 174 | 217 | 272 | 8 | 8 | 12 | 5 | |
| | #2 | 30 | 24 | 164 | 155 | 295 | 347 | 8 | 15 | 5 | 13 | |
| | #3 | 32 | 29 | 132 | 158 | 232 | 295 | 10 | 13 | 7 | 10 | |
| | Mean | 37.67 | 29.56 | 153.00 | 162.22 | 248.11 | 304.56 | 8.56 | 12.11 | 8.00 | 9.44 | |
| | SD | 11.89 | 6.19 | 18.48 | 10.08 | 41.64 | 38.79 | 1.54 | 3.66 | 3.38 | 3.75 | |
| | | #1 | 43 | 23 | 174 | 147 | 238 | 263 | 8 | 7 | 15 | 5 |
| DMSO | #2 | 37 | 27 | 106 | 173 | 271 | 230 | 13 | 17 | 7 | 8 | |
| | #3 | 41 | 31 | 141 | 151 | 282 | 292 | 12 | 12 | 8 | 7 | |
| | Mean | 40.44 | 27.11 | 140.44 | 156.89 | 263.78 | 261.67 | 10.89 | 12.00 | 9.89 | 6.67 | |
| | SD | 3.01 | 4.02 | 34.00 | 13.81 | 22.71 | 30.87 | 2.59 | 5.00 | 4.48 | 1.20 | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Positive Control | #1 | 1740 | 743 | 1220 | 648 | 447 | 736 | 222 | 620 | 234 | 157 | |
| | #2 | 1568 | 935 | 1537 | 684 | 472 | 867 | 239 | 630 | 221 | 121 | |
| | #3 | 1539 | 776 | 1485 | 630 | 452 | 771 | 226 | 715 | 216 | 131 | |
| | Mean | 1615.67 | 817.89 | 1414 | 654.33 | 456.89 | 791.33 | 229.11 | 655.33 | 223.44 | 136.44 | |
| | SD | 108.38 | 102.42 | 169.75 | 27.5 | 13.61 | 68.06 | 8.76 | 52.2 | 9.48 | 18.86 | |
| | | | | | | | | | | | | |
| A N (mg / plate) | #1 | 28 | 29 | 159 | 152 | 310 | 260 | 8 | 14 | 13 | 9 | |
| | #2 | 29 | 20 | 121 | 116 | 279 | 257 | 9 | 19 | 12 | 11 | |
| | #3 | 30 | 24 | 174 | 148 | 293 | 263 | 11 | 16 | 11 | 13 | |
| | Mean | 29.00 | 24.44 | 151.22 | 138.67 | 293.78 | 259.89 | 9.33 | 16.56 | 12.00 | 10.89 | |
| | SD | 1.33 | 4.68 | 27.27 | 19.73 | 15.70 | 2.67 | 1.33 | 2.67 | 0.88 | 2.17 | |
| | | | | | | | | | | | | |
| 0. | #1 | 24 | 26 | 151 | 150 | 268 | 264 | 8 | 14 | 11 | 14 | |
| | #2 | 32 | 42 | 195 | 152 | 241 | 240 | 7 | 9 | 11 | 10 | |
| | #3 | 27 | 31 | 161 | 165 | 255 | 267 | 8 | 11 | 12 | 11 | |
| | Mean | 27.67 | 33.11 | 168.89 | 155.67 | 255.00 | 256.89 | 7.78 | 11.33 | 11.44 | 11.56 | |
| | SD | 4.18 | 7.82 | 23.12 | 8.41 | 13.50 | 15.03 | 0.51 | 2.52 | 0.84 | 2.22 | |
| | | | | | | | | | | | | |
| 1 | #1 | 36 | 29 | 178 | 133 | 260 | 223 | 5 | 8 | 14 | 7 | |
| | #2 | 37 | 32 | 151 | 140 | 265 | 221 | 8 | 0 | 9 | 11 | |
| | #3 | 36 | 31 | 168 | 134 | 273 | 225 | 8 | 7 | 11 | 9 | |
| | Mean | 36.56 | 30.89 | 165.56 | 135.67 | 265.89 | 223.33 | 7.00 | 4.78 | 11.44 | 8.89 | |

| Treatment | Plate | TA98 | | TA100 | | TA102 | | TA1535 | | TA1537 | |
|-----------|-------|-------|-------|--------|-------|--------|--------|--------|------|--------|------|
| | | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- | S9+ | S9- |
| 3 | SD | 0.69 | 1.39 | 13.50 | 3.84 | 6.59 | 2.00 | 1.45 | 4.17 | 2.50 | 2.01 |
| | #1 | 81 | 28 | 85 | 76 | 178 | 225 | 83 | 0 | 6 | 3 |
| | #2 | 47 | 11 | 104 | 112 | 185 | 258 | 50 | 0 | 12 | 9 |
| | #3 | 46 | 60 | 161 | 87 | 192 | 208 | 34 | 0 | 13 | 8 |
| | Mean | 58.00 | 32.89 | 116.78 | 91.44 | 184.78 | 230.22 | 55.56 | 0.00 | 10.56 | 6.44 |
| 5 | SD | 19.92 | 25.24 | 39.50 | 18.31 | 6.83 | 25.24 | 25.13 | 0.00 | 3.72 | 3.29 |
| | #1 | 85 | 0 | 8 | 0 | 134 | 68 | 2 | 0 | 3 | 0 |
| | #2 | 41 | 0 | 0 | 0 | 186 | 90 | 3 | 0 | 3 | 0 |
| | #3 | 49 | 0 | 0 | 0 | 197 | 98 | 3 | 0 | 4 | 0 |
| | Mean | 58.22 | 0.00 | 2.56 | 0.00 | 172.33 | 85.22 | 1.67 | 0.00 | 3.33 | 0.00 |
| | SD | 23.25 | 0.00 | 4.43 | 0.00 | 33.39 | 15.49 | 1.53 | 0.00 | 0.58 | 0.00 |